

(19) **DANMARK**



Patent- og  
Varemærkestyrelsen

(10) **DK/EP 3964502 T3**

(12) **Oversættelse af  
europæisk patentskrift**

- (51) Int.Cl.: **C 07 D 257/00 (2006.01)** **A 61 K 31/41 (2006.01)** **A 61 K 49/00 (2006.01)**  
**A 61 P 35/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2024-07-22**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2024-06-12**
- (86) Europæisk ansøgning nr.: **21198449.7**
- (86) Europæisk indleveringsdag: **2010-03-19**
- (87) Den europæiske ansøgnings publiceringsdag: **2022-03-09**
- (30) Prioritet: **2009-03-19 US 161485 P** **2009-03-19 US 16148409 P**  
**2009-10-02 US 248067 P** **2009-10-06 US 248934 P**
- (62) Stamansøgningsnr: **17169052.2**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR**
- (73) Patenthaver: **The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA**
- (72) Opfinder: **POMPER, Martin G., , Baltimore, Maryland 21212, USA**  
**MEASE, Ronnie C., , Fairfax, Virginia 22030, USA**  
**RAY, Sangeeta, , Ellicott City, Maryland 21042, USA**  
**CHEN, Ying, , Timonium, Maryland 21093, USA**
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **PSMA-MÅLRETNINGSFORBINDELSER OG ANVENDELSER DERAFF**
- (56) Fremdragne publikationer:  
**WO-A1-2009/026177**  
**WO-A2-2009/002529**  
**SACHIN S. CHANDRAN ET AL: "Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)", CANCER BIOLOGY & THERAPY, vol. 7, no. 6, 1 June 2008 (2008-06-01), pages 974-982, XP055020248, ISSN: 1538-4047, DOI: 10.4161/cbt.7.6.5968**  
**BANERJEE SANGEETA R ET AL: "Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 51, no. 15, 14 August 2008 (2008-08-14), pages 4504-4517, XP002577449, ISSN: 0022-2623, DOI: 10.1021/JM800111U [retrieved on 2008-07-19]**  
**YING CHEN ET AL: "Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 51, 25 December 2008 (2008-12-25), pages 7933-7943, XP002614473, ISSN: 0022-2623, DOI: 10.1021/JM801055H [retrieved on 2008-12-03]**  
**MARESCA K P ET AL: "A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 52, 22 January 2009 (2009-01-22), pages 347-357, XP002614472, ISSN:**

Fortsættes ...

0022-2623, DOI: 10.1021/JM800994J [retrieved on 2008-12-29]

SANGEETA RAY BANERJEE ET AL: "68 Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 14, 22 July 2010 (2010-07-22), pages 5333-5341, XP55166168, ISSN: 0022-2623, DOI: 10.1021/jm100623e

Sumith A. Kularatne ET AL: "Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99m Tc-Radioimaging Agents", Molecular Pharmaceutics, vol. 6, no. 3, 1 June 2009 (2009-06-01), pages 790-800, XP55400629, US ISSN: 1543-8384, DOI: 10.1021/mp9000712

SACHIN S. CHANDRAN ET AL: "Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)", CANCER BIOLOGY & THERAPY, vol. 7, no. 6, 1 June 2008 (2008-06-01), pages 974 - 982, XP055020248, ISSN: 1538-4047, DOI: 10.4161/cbt.7.6.5968

BANERJEE SANGEETA R ET AL: "Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 51, no. 15, 14 August 2008 (2008-08-14), pages 4504 - 4517, XP002577449, ISSN: 0022-2623, [retrieved on 20080719], DOI: 10.1021/JM800111U

YING CHEN ET AL: "Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 51, 25 December 2008 (2008-12-25), pages 7933 - 7943, XP002614473, ISSN: 0022-2623, [retrieved on 20081203], DOI: 10.1021/JM801055H

MARESCA K P ET AL: "A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 52, 22 January 2009 (2009-01-22), pages 347 - 357, XP002614472, ISSN: 0022-2623, [retrieved on 20081229], DOI: 10.1021/JM800994J

SANGEETA RAY BANERJEE ET AL: "68 Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 14, 22 July 2010 (2010-07-22), pages 5333 - 5341, XP055166168, ISSN: 0022-2623, DOI: 10.1021/jm100623e

SUMITH A. KULARATNE ET AL: "Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99m Tc-Radioimaging Agents", MOLECULAR PHARMACEUTICS, vol. 6, no. 3, 1 June 2009 (2009-06-01), US, pages 790 - 800, XP055400629, ISSN: 1543-8384, DOI: 10.1021/mp9000712

# DESCRIPTION

Description

## CROSS-REFERENCE TO RELATED APPLICATION

**[0001]** This application claims priority to U.S. Provisional Application Nos. 61/161,484 filed March 19, 2009, 61/161,485, filed March 19, 2009, 61/248,067, filed October 2, 2009, and 61/248,934, filed October 6, 2009. This invention was made using U. S. Government support under NIH grant NIH U24 CA92871. The government has certain rights in this invention.

## BACKGROUND

### Field of the Invention

**[0002]** The present invention relates to prostate specific membrane antigen (PSMA) binding compounds, chemical precursors of PSMA binding compounds and imaging methods of using the compounds. Any references in the description to methods of treatment refer to the compounds, pharmaceutical compositions and medicaments of the invention for use in a method of treatment of the human or animal body by therapy or for diagnosis.

### Background

**[0003]** Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in men in the United States (Cancer Facts & Figures; American Cancer Society: Atlanta, GA, 2009). In 2009, it is estimated that 192,000 men will be diagnosed with prostate cancer and 27,000 men will die of the disease. Only one half of tumors due to PCa are clinically localized at diagnosis and one half of those represent extracapsular spread. Localization of that spread as well as determination of the total body burden of PCa have important implications for therapy, particularly as new combination and focal therapies become available.

**[0004]** The prostate-specific membrane antigen (PSMA), while expressed in prostate tumor epithelium, has a curious property in that it is expressed in the neovasculature of many solid tumors but not in that of prostate cancer (Chang et al., Cancer Res., vol. 59, pp. 3192-3198, 1999; Chang et al., Clin. Cancer Res., vol. 5, pp. 2674-2681, 1999; Gong et al., Cancer

Metastasis Rev., vol. 18, pp. 483-490, 1999; Chang et al., Mol. Urol., vol. 3, pp. 313-320, 1999; Baccala et al., Urology, vol. 70, pp. 385-390, 2007; Chang et al., Urology, vol. 57, pp. 801-805, 2001; Milowsky et al., J. Clin. Oncol., vol. 25, pp. 540-547, 2007). Because of that property, an  $^{111}\text{In}$ -labeled monoclonal antibody to an extracellular epitope of PSMA,  $^{111}\text{In}$ -J591, was capable of identifying renal, bladder, lung, breast, colorectal and pancreatic tumors in a Phase I clinical imaging study (Milowsky et al., J. Clin. Oncol., vol. 25, pp. 540-547, 2007). That study validated  $^{111}\text{In}$ -J591 as a vascular targeting agent in human subjects. Since then other reports have further studied PSMA expression in certain tumor types. Baccala et al. noted that clear cell renal cell carcinoma expresses significantly more PSMA in its neovasculature than does the papillary variety (Baccala et al., Urology, vol. 70, pp. 385-390, 2007). Furthermore, angiomyolipoma, a benign renal lesion, did not express PSMA. As an enzyme with an extracellular active site, PSMA represents an excellent target for imaging and therapy directed toward solid tumor neovasculature in addition to prostate cancer itself. PSMA-based agents can report on the presence of this marker, which is increasingly recognized as an important prognostic determinate in PCa (Murphy et al., Urology, vol. 51, pp. 89-97, 1998). It is also the target for a variety of new PCa therapies (Galsky et al., J Clin Oncol, vol. 26, pp. 2147-2154, 2008).

**[0005]** ProstaScint™ is an  $^{111}\text{In}$ -labeled monoclonal antibody against PSMA that is clinically available for imaging PCa. Radioimmunotherapy based on ProstaScint™ and radiolabeled variations of this antibody are fraught with similar difficulties to the use of radiolabeled antibodies for imaging, including prolonged circulation times, poor target to nontarget tissue contrast, unpredictable biological effects and the occasional need for pretargeting strategies, limiting the utility of these agents (Lange, P. H., Urology, vol. 57, pp. 402-406, 2001; Haseman et al., Cancer Biother Radiopharm, vol. 15, pp. 131-140, 2000; Rosenthal et al., Tech Urol, vol. 7, pp. 27-37, 2001). Furthermore, antibodies may have less access to tumor than low molecular weight agents, which can be manipulated pharmacologically.

**[0006]** The development of low molecular weight radiotherapeutic agents is much different from developing radiopharmaceuticals for imaging in that longer tumor residence times can often be important for the former.

**[0007]** Complete detection and eradication of primary tumor and metastatic foci are required to effect a cure in patients with cancer; however, current preoperative assessment often misses small metastatic deposits. More sensitive imaging techniques than computed tomography, magnetic resonance imaging and even positron emission tomography (PET), which can be used easily in the operating suite, are required. An old technique, recently revisited because of improved optics and fluorescent dye chemistry, is intraoperative photodiagnosis (PDD) (Toda, Keio J. Med., vol. 57, pp. 155-161, 2008). Fluorescein dyes have been used intraoperatively to identify brain tumors and verify the clarity of tumor margins since 1948 (Toda, Keio J. Med., vol. 57, pp. 155-161, 2008). A recent report describes its utility in identifying brain metastases (Okuda et al., Minim. Invasive Neurosurg., vol. 50, pp. 382-384, 2007). A long history of the use of 5-aminolevulinic acid (5-ALA) for brain tumor resection is also evident, and its use has

been associated with improvement in progression-free survival (Stummer et al., *Lancet Oncol.*, vol. 7, pp. 392-401, 2006). PDD can be performed easily during surgery due to the lack of a need for complex imaging equipment. All that is needed is a lightemitting diode to excite the fluorophore, which can be administered systemically or "painted" on the tissue directly. More recent incarnations of PDD have used quantum dots (Arndt-Jovin et al., *IEEE Trans Nanobioscience*, 2009), and more advanced dyes, such as indocyanine green (ICG) (Gotoh et al., *J. Surg. Oncol.*, 2009), which emit in the near-infrared (NIR) region of the spectrum, enabling reasonable tissue penetration of emitted (and detected) light. Applications have included nontargeted approaches, such as preoperative evaluation of the vascular integrity of surgical flaps or identification of nodules of hepatocellular carcinoma (Matsui et al., *Plast. Reconstr. Surg.*, vol. 123, pp. 125e-127e, 2009). Targeted approaches are also emerging, such as use of a fluorophore-conjugated anti-CEA antibody to identify colon or pancreatic cancer (Kaushal et al., *J. Gastrointest. Surg.*, vol. 12, pp. 1938-1950, 2008), or the use of NIR activatable probes that emit light only when cleaved by a tumor-associated protease (Sheth et al., *Gynecol. Oncol.*, vol. 112, pp. 616-622, 2009).

**[0008]** Recently, the application of  $^{68}\text{Ga}$ -labeled peptides has attracted considerable interest for cancer imaging because of the physical characteristics of Ga-68 (Reubi et al., *J Nucl Med*, vol. 49, pp. 1735-1738, 2008). Ga-68 is available from an in-house  $^{68}\text{Ge}/^{68}\text{Ga}$  generator ( $^{68}\text{Ge}$ ,  $t_{1/2} = 270.8$  day), which renders it independent of an onsite cyclotron. Therefore,  $^{68}\text{Ga}$ -based PET agents possess significant commercial potential and serve as a convenient alternative to cyclotron-based isotopes for positron emission tomography (PET), such as  $^{18}\text{F}$  or  $^{124}\text{I}$ .  $^{68}\text{Ga}$  has a high positron-emitting fraction (89% of its total decay). The maximum positron energy of  $^{68}\text{Ga}$  (max. energy = 1.92 MeV, mean = 0.89 MeV) is higher than that of  $^{18}\text{F}$  (max = 0.63 MeV, mean = 0.25 MeV). However, a study of spatial resolution using Monte Carlo analysis revealed that under the assumption of 3 mm spatial resolution for most PET detectors, the full-width-at-half-maximum (FWHM) of  $^{18}\text{F}$  and  $^{68}\text{Ga}$  are indistinguishable in soft tissue (3.01 mm vs. 3.09 mm) (Sanchez-Crespo et al., *Eur J Nucl Med Mol Imaging*, vol. 31, pp. 44-51, 2004). That finding implies that with the standard spatial resolution of 5 to 7 mm for current clinical scanners, image quality using  $^{68}\text{Ga}$ -based radiotracers will likely be indistinguishable from that of  $^{18}\text{F}$ -based agents, stimulating interest in the development of  $^{68}\text{Ga}$ -labeled compounds for medical imaging (Sanchez-Crespo et al., *Eur J Nucl Med Mol Imaging*, vol. 31, pp. 44-51, 2004; Khan et al., *Eur J Surg Oncol*, vol. 35, pp. 561-567, 2009; Fani et al., *Contrast Media Mol Imaging*, vol. 3, pp. 67-77, 2008). With a physical half-life of 68 min,  $^{68}\text{Ga}$  is also matched nicely to the pharmacokinetics of many peptides used for imaging. Few  $^{68}\text{Ga}$ -labeled, mechanism-based radiotracers for prostate cancer have been reported previously, and none for PSMA. Furthermore,  $^{68}\text{Ga}$  is introduced to biomolecules through macrocyclic chelators, which allows possible kit formulation and wide availability of the corresponding imaging agents. WO 2009/026177 A1 discloses conjugates of three moieties, namely of a prostate specific membrane antigen (PSMA) binding ligand, a linker and a drug. WO 2009/002529 A2 discloses conjugates of three moieties, namely a metal chelator, a linker

and a PSMA inhibitor.

Chandran et al. (Characterization of a Targeted Nanoparticle Functionalized with a Urea-Based Inhibitor of Prostate Specific Membrane Antigen (PSMA), *Cancer Biology & Therapy*, Vol. 7, No. 6, 2008, 974-982) disclose nanoparticles exhibiting surfaces decorated with a urea-based small molecule peptidomimetic inhibitor of PSMA.


Banerjee et al. (Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA), *J. Med. Chem.*, 51, 2008, 4504-4517) disclose the preparation of radiolabeled compounds consisting of a Tc/Re chelating agent, a linker and a PSMA inhibitor.

Chen et al. (Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer, *J. Med. Chem.*, 51, 2008, 7933-7943) disclose the preparation of a Lys-C(O)-Glu template for the development of single photon emission computed tomography and positron emission tomography imaging agents of prostate cancer. Maresca et al. (A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer, *J. Med. Chem.*, 52, 2009, 347-357) disclose design and synthesis of a series of glutamate-urea heterodimeric inhibitors of PSMA

## SUMMARY OF THE INVENTION


**[0009]** The present invention satisfies the long standing and unmet need for new imaging and therapeutic compounds for targeting prostate cancer and cancer angiogenesis. The present invention, in particular, provides therapeutic compounds and imaging agents which differ from the prior art in modifications which were not previously known or suggested. Furthermore, the invention provides imaging agents that offer better contrast between target tissues and non-target tissues. The invention also provides compounds with greater cellular retention and low molecular weight. Embodiments not falling within the scope of the claims are disclosed and for information only.

**[0010]** Disclosed embodiments not covered by the invention include compounds having the structure




wherein the subunits associated with elements p, q, r, and s may be in any order. Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4, and R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl.


**[0011]** Variable r is 0 or 1. Tz is a triazole group selected from the group consisting of




where L<sup>1</sup> is



L<sup>2</sup> is



or





X<sup>1</sup> is -NRC(O)-, -NRC(O)NR-, -NRC(S)NR-, or -NRC(O)O-; X<sup>2</sup> is -C(O)NR-, -NRC(O)NR-, -NRC(S)NR-, or -OC(O)NR-; R<sup>5</sup> is H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>6</sup>, where R<sup>6</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl; b is 1, 2, 3, or 4; and d is 1, 2, 3, or 4.

**[0012]** Variable q is 0 or 1. W is -NRC(O)-, -NRC(O)NR-, -NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-; R<sup>2</sup> and R<sup>3</sup> are independently H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>4</sup>, where R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl, wherein if one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>H or CO<sub>2</sub>R<sup>2</sup>, then the other is H; n is 1, 2, 3, 4, 5 or 6.

**[0013]** Variable s is 0 or 1. Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O); and m is 1, 2, 3, 4, 5, or 6.


**[0014]** Variable p is 0, 1, 2, or 3, and when p is 2 or 3, each R<sup>1</sup> may be the same or different. R<sup>1</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl.


**[0015]** G is a moiety selected from the group consisting of



where Ch is a metal chelating moiety, optionally including a chelated metal; FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum; one of A and A' is Ch and the other is FG; V and V' are independently -C(O)-, -NRC(O)-, -NRC(S)-, or -OC(O)-; and g is 1, 2, 3, 4, 5, or 6. The following conditions also apply:


1. **1)** when G is






and r is 0, then q and s are both 1;

2. **2)** when G is




and r is 0, then q and s are both 0 or both 1;

3. **3)** when G is




then p is 0 and R<sup>2</sup> is H, and the structure optionally includes a chelated metal ion.

4. **4)** when G is




and r is 0, then if p is 0, then one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>R<sup>2</sup>, and the other is H; and

5. **5)** when g is



then r is 0.

**[0016]** Embodiments include compounds having the structure



wherein:

Z is tetrazole or CO<sub>2</sub>Q;

each Q is independently selected from hydrogen or a protecting group;

a is 1, 2, 3, or 4;

R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

Ch is a metal chelating moiety optionally including a chelated metal, wherein Ch further includes any additional atoms or linkers necessary to attach the metal chelating moiety to the rest of the compound;

W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-;

Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O);

V is -C(O)-, -NRC(O)-, -NRC(S)-, or -OC(O)-;

m is 1, 2, 3, 4, 5, or 6;


n is 1, 2, 3, 4, 5 or 6;

p is 2;

R<sup>1</sup> is C<sub>2</sub>-C<sub>12</sub> aryl, wherein the aryl may be substituted or unsubstituted and R<sup>1</sup> may be the same or different;

R<sup>2</sup> and R<sup>3</sup> are independently H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>4</sup>, wherein R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl, wherein when one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>H or CO<sub>2</sub>R<sup>4</sup>, the other is H.

**[0017]** Some embodiments further include a chelated metal. In some embodiments, the chelated metal is Tc, In, Ga, Y, Lu, Re, Cu, Ac, Bi, Pb, Sm, Sc, Co, Ho, Gd, Eu, Tb, or Dy. In some embodiments, the chelated metal is an isotope, for example. In some embodiments, the isotope is Tc-94m, Tc-99m, In-111, Ga-67, Ga-68, Y-86, Y-90, Lu-177, Re-186, Re-188, Cu-64, Cu-67, Co-55, Co-57, Sc-47, Ac-225, Bi-213, Bi-212, Pb-212, Sm-153, Ho-166, or Dy-166. Embodiments of the disclosure, but not part of the invention include compounds having the structure




optionally including a chelated metal ion. Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, and a is 1, 2, 3, or 4. R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-. Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O)-;

**[0018]** In exemplary embodiments of the disclosure, but not part of the invention m is 1, 2, 3, 4, 5, or 6; n is 1, 2, 3, 4, 5 or 6; q is 0 or 1; and s is 0 or 1. R<sup>3</sup> is H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>4</sup>, where R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl. Some embodiments further include a chelated metal ion. In some embodiments, the metal ion is Tc, Re, Cu, or Ga. In some embodiments, the metal ion is Tc-99m, Re-186, Re-188, Cu-64, or Ga-68. In some embodiments, the metal ion is Tc-99m.


**[0019]** Embodiments of the disclosure, but not part of the invention include compounds having the structure






where p, q, and s are in the order drawn, and q and s are either both 0 or both 1. Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, and a is 1, 2, 3, or 4. FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum. R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. V is -C(O)- or -NRC(O)- or -NRC(S)-. W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-. Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O). In exemplary embodiments m is 1, 2, 3, 4, 5, or 6; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, or 3, and when p is 2 or 3, each R<sup>1</sup> may be the same or different. R<sup>1</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl. R<sup>2</sup> and R<sup>3</sup> are independently H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>2</sup>, where R<sup>2</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl, wherein when one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>H or CO<sub>2</sub>R<sup>2</sup>, the other is H. In some embodiments, the fluorescent dye moiety emits in the near infrared spectrum.


**[0020]** Embodiments of the disclosure, but not part of the invention include compounds having the structure




wherein Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, and a is 1, 2, 3, or 4. One of A and A' is Ch and the other is FG, where FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum and Ch is metal chelating moiety optionally including a chelated metal. R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. V or V' are independently -C(O)-, -NRC(O)-, or -NRC(S)-. W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-. Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O). In exemplary embodiments m is 1, 2, 3, 4, 5, or 6; n is 1, 2, 3, 4, 5 or 6; and g is 1, 2, 3, 4, 5, or 6; p is 0, 1, 2, or 3, and when p is 2 or 3, each R<sup>1</sup> may be the same or different. R<sup>1</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl. R<sup>2</sup> and R<sup>3</sup> are independently H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>4</sup>, where R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl, wherein when one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>H or CO<sub>2</sub>R<sup>2</sup>, the other is H. In some embodiments, the fluorescent dye moiety emits in the near infrared spectrum. Some embodiments further include a chelated metal.

**[0021]** Embodiments of this paragraph of the disclosure, but not part of the invention include compounds having the structure








wherein subunits associated with p, q, r, and s may be in any order. Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, and a is 1, 2, 3, or 4. R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. In this exemplary embodiment r is 1. Tz is a triazole group having the structure



where L<sup>1</sup> is



X<sup>1</sup> is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, or -NRC(O)O-; X<sup>2</sup> is -C(O)NR-, -NRC(O)NR-, NRC(S)NR-, or -OC(O)NR-; R<sup>5</sup> is H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>6</sup>, where R<sup>6</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl; b is 1, 2, 3, or 4; and d is 1, 2, 3, or 4. In exemplary embodiments q is 0 or 1, W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-; n is 1, 2, 3, 4, 5 or 6; and R<sup>2</sup> and R<sup>3</sup> are independently H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>4</sup>, where R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl, wherein if one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>H or CO<sub>2</sub>R<sup>2</sup>, then the other is H. In exemplary embodiments s is 0 or 1; Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O); and m is 1, 2, 3, 4, 5, or 6. In exemplary embodiments p is 0, 1, 2, or 3, and when p is 2 or 3, each R<sup>1</sup> may be the same or different; and R<sup>1</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl. G<sup>1</sup> is a moiety selected from the group consisting of



where Ch is a metal chelating moiety, optionally including a chelated metal; FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum; one of A and A' is Ch and the other is FG; V and V' are each independently -C(O)-, -NRC(O)-, -NRC(S)-, or -OC(O)-; and g is 1, 2, 3, 4, 5, or 6. In some embodiments, the fluorescent dye moiety emits in the near infrared spectrum. Some embodiments include a chelated metal.

**[0022]** Embodiments of the invention include methods of imaging one or more cells, organs or tissues by exposing the cell to or administering to a organism an effective amount of a compound discussed above, where the compound includes a fluorescent dye moiety, or a metal isotope suitable for imaging.

**[0023]** Embodiments include methods of treating a tumor comprising administering a therapeutically effective amount of a compound discussed above, where the compound includes a therapeutically effective radioisotope.

**[0024]** Embodiments of the disclosure, but not part of the invention include methods for sorting cells by exposing the cells to a compound discussed above, where the compound includes a fluorescent dye moiety, followed by separating cells which bind the compound from cells which do not bind the compound.

**[0025]** Embodiments of the disclosure, but not part of the invention of the invention include methods of intraoperative tumor mapping comprising administering an effective amount of a compound discussed above to a subject, where the compound includes a fluorescent dye moiety.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

##### **[0026]**

**Figure 1** shows SPECT-CT images of a PSMA+ LNCaP tumor-bearing mouse injected intravenously with exemplary compound [<sup>99m</sup>Tc]SRV32.

**Figure 2.** GE eXplore VISTA pseudodynamic PET image (co-registered with the corresponding CT image) of a PSMA+ LNCaP tumor-bearing mouse injected intravenously with 0.2 mCi (7.4 MBq) of exemplary compound [<sup>68</sup>Ga]SRV27.

**Figure 3.** GE eXplore VISTA PET image (co-registered with the corresponding CT image) of a PSMA+ PIP and PSMA- flu tumor-bearing mouse injected intravenously with 0.2 mCi (7.4 MBq) of exemplary compound [<sup>68</sup>Ga]SRV100.

**Figure 4** shows a synthetic scheme for exemplary compound SRV100 and [<sup>111</sup>In]SRV100.

**Figure 5** shows SPECT-CT images of a PSMA+ PC-3 PIP tumor-bearing mouse injected intravenously with exemplary compound [<sup>111</sup>In]SRV27.

**Figure 6** shows SPECT-CT images of a PSMA+ PC-3 PIP tumor-bearing mouse injected intravenously with exemplary compound [<sup>111</sup>In]SRV100.

**Figure 7** shows SPECT-CT images of a PSMA+ PC-3 PIP tumor-bearing mouse injected

intravenously with exemplary dual modality compound [ $^{111}\text{In}$ ]SRV73.

**Figure 8** shows the absorbance and emission spectra, and quantum yield of exemplary compound YC-27.

**Figure 9** shows the fluorescence decay of exemplary compound YC-27.

**Figure 10** shows an  $\text{IC}_{50}$  curve of compound YC-27 using a fluorescence-based NAALADase assay

**Figure 11** shows *in vivo* imaging of a NOD/SCID mouse (mouse #1), bearing PC3-PIP (forward left flank) and PC3-flu (forward right flank) tumors. Mouse #1 received 10 nmol of YC-27 and dorsal (animal prone) and ventral (animal supine) views were obtained. Dorsal and ventral views at 40 min p.i. (A, B, respectively); 18.5 h (C, D); 23 h (E, F); 42.5 h (G, H); 68 h (I, J). Dorsal view of pre-injection image (K). Dorsal and ventral views 70.5 h p.i. (L, M). Images after midline laparotomy (N) and individually harvested organs (O) on a Petri dish at 70.5 h p.i.. Images were scaled to the same maximum (arbitrary units).

**Figure 12** shows *in vivo* imaging of a NOD/SCID mouse (mouse #2) (left panel), bearing PC3-PIP (forward left flank) and PC3-flu (forward right flank) tumors. Mouse #2 received 1 nmol of YC-27 and dorsal (animal prone) and ventral (animal supine) views were obtained. Dorsal and ventral views of the pre-injection image (A, B, respectively); 10 min p.i. (C, D); 20.5 h (E, F); 24 h (G, H). Images after midline laparotomy (I) and individually harvested organs (J) on a Petri dish at 24 h p.i.. *Right Panels:* Mouse #3 in same orientation as mouse #2. Mouse #3 received 1 nmol of YC-27 co-injected with 1  $\mu\text{mol}$  of DCIBzL, which served as a blocking agent to test binding specificity. Images were scaled to the same maximum (arbitrary units).

**Figure 13** shows SPECT-CT images of a PSMA+ LNCaP tumor-bearing mouse injected intravenously with exemplary compound [ $^{99\text{m}}\text{Tc}$ ]SRVI34B.

**Figure 14** shows SPECT-CT images of a PSMA+ PC3-PIP tumor-bearing mouse injected intravenously with exemplary compound [ $^{99\text{m}}\text{Tc}$ ]SRVI34B.

**Figure 15** shows SPECT-CT images of a PSMA+ PC3-PIP (forward left flank) and PSMA- PC3-flu (forward right flank) tumor-bearing mouse injected intravenously with exemplary compound [ $^{99\text{m}}\text{Tc}$ ]SRVI34A.

**Figure 16** shows SPECT-CT images of a PSMA+ PC3-PIP (forward left flank) and PSMA- PC3-flu (forward right flank) tumor-bearing mouse injected intravenously with exemplary compound [ $^{99\text{m}}\text{Tc}$ ]SRVI34B.

**Figure 17** shows PC3-PIP and PC3-flu cells treated with fluorescent compound YC-VIII-36 (green, top left) and DAPI (blue), and PC3-PIP and PC3-flu cells treated with both YC-VIII-36 and PSMA inhibitor, PMPA.

**Figure 18** shows PC3-PIP cells treated with DAPI (blue) and varying concentrations of YC-VIII-

36 (green).

**Figure 19** shows time dependent internalization of YC-VIII-36 into PC3-PIP cells treated with YC-VIII-36 (green) and DAPI (blue).

**Figure 20** shows titration and detection of varying amounts of YC-VIII-36 injected subcutaneously into a nude mouse. (IVIS spectrum with 10 second exposure followed by spectral unmixing)

**Figure 21** shows fluorescence images of a PSMA+ PC3-PIP and PSMA- PC3-flu tumor-bearing mouse injected intravenously with exemplary compound YC-VIII-36.

**Figure 22** shows fluorescence images of a PSMA+ PC3-PIP and PSMA- PC3-flu tumor-bearing mouse injected intravenously with exemplary compound YC-VIII-36 180 minutes after injection (top) and biodistribution of exemplary compound YC-VIII-36 180 minutes after injection (bottom).

**Figure 23** shows FACS analysis showing the percent subpopulation of PSMA positive cells in PC3-flu, PC3-PIP, and LNCaP cells.

**Figure 24** shows cell sorting results for PC3-PIP cells treated with exemplary compound YC-VIII-36, including initial percentage (top center), and after 3 passages of sorting (bottom).

**Figure 25** shows the number of spiked PIP-pos cells into 10 million of PC3-flu detectable by 100 nM compound YC-VIII-36 in flow cytometry (BD LSR-II). Gate P1 is total number of single cells counted; gate P2 at higher intensity is the number of Pip-pos cells detected and gate P3 at lower intensity.

## DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

[0027] Some embodiments of the current invention are discussed in detail below. In describing embodiments, specific terminology is employed for the sake of clarity..

[0028] Where a range of values is provided in the present application, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The end values of any range are included in the range.

### Definitions

[0029] The following terms below generally have the meaning that would be readily

understood by persons skilled in the art. The definitions are provided herein for clarity. Where a definition excludes an art-recognized meaning, the term should be taken to have the meaning set forth below. Where the art-recognized meaning and the meaning below differ but are not exclusive, the intended meaning is clear by the context in which it is used.

**[0030]** As used herein, "agent" is a non-peptide, small molecule compound.

**[0031]** By "cell substrate" is meant the cellular or acellular material (e.g., extracellular matrix, polypeptides, peptides, or other molecular components) that is in contact with the cell.

**[0032]** By "control" is meant a standard or reference condition.

**[0033]** By "disease" is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, organ or subject.

**[0034]** By "effective amount" is meant a quantity sufficient to produce a measurable difference, when compared with a control. For example, an amount sufficient to produce a measurable image, when the compound is used for imaging, or an amount sufficient to ameliorate the symptoms of a disease, when the compound is used for therapy. The effective amount of an active therapeutic agent for the treatment of a disease or injury varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending clinician will decide the appropriate amount and dosage regimen.

**[0035]** By "modifies" is meant alters. An agent that modifies a cell, substrate, or cellular environment produces a biochemical alteration in a component (e.g., polypeptide, nucleotide, or molecular component) of the cell, substrate, or cellular environment.

**[0036]** As used herein, the terms "prevent," "preventing," "prevention," "prophylactic treatment" and the like refer to reducing the probability of developing a disorder or condition in a subject, who does not have, but is at risk of or susceptible to developing a disorder or condition.

**[0037]** By "subject" is meant a mammal, including, but not limited to, a human or nonhuman mammal, such as a bovine, equine, canine, ovine, or feline.

**[0038]** By "therapeutic delivery device" is meant any device that provides for the release of a therapeutic agent. Exemplary therapeutic delivery devices include tablets and pills, described below, as well as syringes, osmotic pumps, indwelling catheters, delayed-release and sustained-release biomaterials.

**[0039]** As used herein, the terms "treat," "treating," "treatment," "therapeutic" and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.

**[0040]** The compounds herein described may have one or more asymmetric centers or planes. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms (racemates), by asymmetric synthesis, or by synthesis from optically active starting materials. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral (enantiomeric and diastereomeric), and racemic forms, as well as all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.

**[0041]** The compounds herein described may have one or more charged atoms. For example, the compounds may be zwitterionic, but may be neutral overall. Other embodiments may have one or more charged groups, depending on the pH and other factors. In these embodiments, the compound may be associated with a suitable counter-ion. It is well known in the art how to prepare salts or exchange counter-ions. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Counter-ions may be changed, for example, by ion-exchange techniques such as ion-exchange chromatography. All zwitterions, salts and counter-ions are intended, unless the counter-ion or salt is specifically indicated. In certain embodiments, the salt or counter-ion may be pharmaceutically acceptable, for administration to a subject. Pharmaceutically acceptable salts are discussed later.

**[0042]** As used herein, a "protecting group" is a chemical substituent which can be selectively removed by readily available reagents which do not attack the regenerated functional group or other functional groups in the molecule. Suitable protecting groups are known in the art and continue to be developed. Suitable protecting groups may be found, for example in Wutz et al. ("Greene's Protective Groups in Organic Synthesis, Fourth Edition," Wiley-Interscience, 2007). Protecting groups for protection of the carboxyl group, as described by Wutz et al. (pages 533-643), are used in certain embodiments. In some embodiments, the protecting group is removable by treatment with acid. Specific examples of protecting groups include but are not limited to, benzyl, p-methoxybenzyl (PMB), tertiary butyl (Bu), methoxymethyl (MOM), methoxyethoxymethyl (MEM), methylthiomethyl (MTM), tetrahydropyranyl (THP), tetrahydrofuranyl (THF), benzyloxymethyl (BOM), trimethylsilyl (TMS), triethylsilyl (TES), t-butyl dimethylsilyl (TBDMS), and triphenylmethyl (trityl, Tr). Persons skilled in the art will recognize appropriate situations in which protecting groups are required and will be able to select an appropriate protecting group for use in a particular circumstance.

**[0043]** As used herein, "alkyl" is intended to include branched, straight-chain, and cyclic saturated aliphatic hydrocarbon groups. Examples of alkyl include, but are not limited to, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *tert*-butyl, *n*-pentyl, and *sec*-pentyl. In certain embodiments, alkyl groups are C<sub>1</sub>-C<sub>6</sub> alkyl groups or C<sub>1</sub>-C<sub>4</sub> alkyl groups. Particular alkyl groups are methyl, ethyl, propyl, butyl, and 3-pentyl. The term "C<sub>1</sub>-C<sub>6</sub> alkyl" as used herein means straight-chain, branched, or cyclic C<sub>1</sub>-C<sub>6</sub> hydrocarbons which are completely saturated and hybrids thereof such as (cycloalkyl)alkyl. Examples of C<sub>1</sub>-C<sub>6</sub> alkyl substituents include methyl (Me), ethyl (Et), propyl (including *n*-propyl (*n*-Pr, <sup>n</sup>Pr), *iso*-propyl (*i*-Pr, <sup>i</sup>Pr), and cyclopropyl (c-Pr, <sup>c</sup>Pr)), butyl (including *n*-butyl (*n*-Bu, <sup>n</sup>Bu), *iso*-butyl (*i*-Bu, <sup>i</sup>Bu), *sec*-butyl (*s*-Bu, <sup>s</sup>Bu), *tert*-butyl (*t*-Bu, <sup>t</sup>Bu), or cyclobutyl (c-Bu, <sup>c</sup>Bu)), and so forth. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Cycloalkyl groups typically will have 3 to about 8 ring members. In the term "(cycloalkyl)alkyl", cycloalkyl, and alkyl are as defined above, and the point of attachment is on the alkyl group. This term encompasses, but is not limited to, cyclopropylmethyl, cyclopentylmethyl, and cyclohexylmethyl. The alkyl group may be substituted or unsubstituted. Substituents are not counted towards the total number of atoms in the alkyl group, so long as the total atoms in the substituent(s) are not larger than the alkyl group.

**[0044]** As used herein, the term "aryl" includes aromatic groups that contain 1 to 3 separate or fused rings and from 2 to about 12 carbon atoms, and up to 3 heteroatoms as ring members. Examples of heteroatoms include nitrogen, oxygen or sulfur atoms. The aryl group may have 0, 1, 2 or 3 heteroatoms as ring members. Examples of aryl groups include but are not limited to phenyl, biphenyl and naphthyl, including 1-naphthyl and 2-naphthyl. Examples of aryl groups having heteroatoms include quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidyl, furanyl, pyrrolyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, and benzothiazolyl, among others. The aryl group may be substituted or unsubstituted. Substituents are not counted towards the total number of atoms in the aryl group, so long as the total atoms in the substituent(s) are not larger than the aryl group.


**[0045]** As used herein, the term "alkylaryl" includes alkyl groups, as defined above, substituted by aryl groups, as defined above. The aryl group may be connected at any point on the alkyl group. The term C<sub>4</sub>-C<sub>16</sub> alkylaryl includes alkylaryl groups having a total of 4 to 16 carbon atoms, counting the carbon atoms on the alkyl group and aryl group together. Examples of alkylaryl groups include but are not limited to benzyl (phenylmethyl), phenylethyl, and naphthylmethyl. The alkylaryl group may be substituted or unsubstituted. Substituents are not counted towards the total number of atoms in the alkylaryl group, so long as the total atoms in the substituent(s) are not larger than the alkylaryl group.

**[0046]** The term "substituted," as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a substituent, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound. When


a substituent is oxo (keto, i.e., =O), then 2 hydrogens on an atom are replaced. The present invention is intended to include all isotopes (including radioisotopes) of atoms occurring in the present compounds. When the compounds are substituted, they may be so substituted at one or more available positions, typically 1, 2, 3 or 4 positions, by one or more suitable groups such as those disclosed herein. Suitable groups that may be present on a "substituted" group include e.g., halogen; cyano; hydroxyl; nitro; azido; amino; alkanoyl (such as a C<sub>1</sub>-C<sub>6</sub> alkanoyl group such as acyl or the like); carboxamido; alkyl groups (including cycloalkyl groups, having 1 to about 8 carbon atoms, for example 1, 2, 3, 4, 5, or 6 carbon atoms); alkenyl and alkynyl groups (including groups having one or more unsaturated linkages and from 2 to about 8, such as 2, 3, 4, 5 or 6, carbon atoms); alkoxy groups having one or more oxygen linkages and from 1 to about 8, for example 1, 2, 3, 4, 5 or 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those having one or more thioether linkages and from 1 to about 8 carbon atoms, for example 1, 2, 3, 4, 5 or 6 carbon atoms; alkylsulfinyl groups including those having one or more sulfinyl linkages and from 1 to about 8 carbon atoms, such as 1, 2, 3, 4, 5, or 6 carbon atoms; alkylsulfonyl groups including those having one or more sulfonyl linkages and from 1 to about 8 carbon atoms, such as 1, 2, 3, 4, 5, or 6 carbon atoms; aminoalkyl groups including groups having one or more N atoms and from 1 to about 8, for example 1, 2, 3, 4, 5 or 6, carbon atoms; carbocyclic aryl having 4, 5, 6 or more carbons and one or more rings, (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted aromatic); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, (e.g. benzyl); arylalkoxy having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms (e.g. O-benzyl); or a saturated, unsaturated, or aromatic heterocyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms, (e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl). Such heterocyclic groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen and amino.

**[0047]** As used herein, where an internal substituent is flanked by bonds (for example -NRC(O)-) the order of the atoms is fixed, the orientation of the group may not be reversed, and is inserted into a structure in the orientation presented. In other words -NRC(O)- is not the same as -C(O)NR-. As used herein the term C(O) (for example -NRC(O)-) is used to indicate a carbonyl (C=O) group, where the oxygen is bonded to the carbon by a double bond.

**[0048]** A substituent bearing a broken bond, such as the example shown below, means that the substituent is directly bonded to the molecule at the indicated position. No additional methylene (CH<sub>2</sub>) groups are implied.



[0049] Substituents bearing two broken bonds, such as the example shown below, means that the orientation of the atoms is as-indicated, left to right and should be inserted into a molecule in the orientation shown. No additional methylene (CH<sub>2</sub>) groups are implied unless specifically indicated.




**Embodiments**


[0050] As described herein, all embodiments or subcombinations may be used in combination with all other embodiments or subcombinations, unless mutually exclusive.

[0051] In some of the following embodiments, Z is CO<sub>2</sub>Q. In some of the following embodiments, Q is H. In some of the following embodiments, m is 4, 5, or 6. In some of the following embodiments, m is 6. In some of the following embodiments, n is 2, 3, or 4. In some of the following embodiments, n is 3. In some of the following embodiments, a is 3 or 4. In some of the following embodiments, a is 4. In some of the following embodiments, Y is -C(O)-. In some of the following embodiments, W is -NHC(O)-.

[0052] Embodiments of the disclosure include compounds having the structure




wherein the subunits associated with elements p, q, r, and s may be in any order. Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4, and R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. It is part of the invention as far as G is




p=2, q=1, r=0, and s=1.

[0053] Variable r is 0 or 1. Tz is a triazole group selected from the group consisting of




where L<sup>1</sup> is




L<sup>2</sup> is

s . . . . . s



or





$\text{X}^1$  is  $-\text{NRC}(\text{O})-$ ,  $-\text{NRC}(\text{O})\text{NR}-$ ,  $-\text{NRC}(\text{S})\text{NR}-$ , or  $-\text{NRC}(\text{O})\text{O}-$ ;  $\text{X}^2$  is  $-\text{C}(\text{O})\text{NR}-$ ,  $-\text{NRC}(\text{O})\text{NR}-$ ,  $-\text{NRC}(\text{S})\text{NR}-$ , or  $-\text{OC}(\text{O})\text{NR}-$ ;  $\text{R}^5$  is H,  $\text{CO}_2\text{H}$ , or  $\text{CO}_2\text{R}^6$ , where  $\text{R}^6$  is a  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_2$ - $\text{C}_{12}$  aryl, or  $\text{C}_4$ - $\text{C}_{16}$  alkylaryl;  $b$  is 1, 2, 3, or 4; and  $d$  is 1, 2, 3, or 4.

**[0054]** Variable  $q$  is 0 or 1.  $W$  is  $-\text{NRC}(\text{O})-$ ,  $-\text{NRC}(\text{O})\text{NR}-$ ,  $\text{NRC}(\text{S})\text{NR}-$ ,  $-\text{NRC}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{NR}-$ ,  $-\text{OC}(\text{O})-$ ,  $-\text{C}(\text{O})\text{NR}-$ , or  $-\text{C}(\text{O})\text{O}-$ ;  $\text{R}^2$  and  $\text{R}^3$  are independently H,  $\text{CO}_2\text{H}$ , or  $\text{CO}_2\text{R}^4$ , where  $\text{R}^4$  is a  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_2$ - $\text{C}_{12}$  aryl, or  $\text{C}_4$ - $\text{C}_{16}$  alkylaryl, wherein if one of  $\text{R}^2$  and  $\text{R}^3$  is  $\text{CO}_2\text{H}$  or  $\text{CO}_2\text{R}^2$ , then the other is H;  $n$  is 1, 2, 3, 4, 5 or 6.

**[0055]** Variable  $s$  is 0 or 1.  $Y$  is  $-\text{C}(\text{O})-$ ,  $-\text{NRC}(\text{O})-$ ,  $-\text{NRC}(\text{S})-$ ,  $-\text{OC}(\text{O})-$ ; and  $m$  is 1, 2, 3, 4, 5, or 6.


**[0056]** Variable  $p$  is 0, 1, 2, or 3, and when  $p$  is 2 or 3, each  $\text{R}^1$  may be the same or different.  $\text{R}^1$  is H,  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_2$ - $\text{C}_{12}$  aryl, or  $\text{C}_4$ - $\text{C}_{16}$  alkylaryl.

**[0057]**  $G$  is a moiety selected from the group consisting of




where Ch is a metal chelating moiety, optionally including a chelated metal; FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum; one of A and A' is Ch and the other is FG; V and V' are independently  $-\text{C}(\text{O})-$ ,  $-\text{NRC}(\text{O})-$ ,  $-\text{NRC}(\text{S})-$ , or  $-\text{OC}(\text{O})-$ ; and  $g$  is 1, 2, 3, 4, 5, or 6. The following conditions also apply:

1. **1)** when  $G$  is




and  $r$  is 0, then  $q$  and  $s$  are both 1;

2. **2)** when  $G$  is




and  $r$  is 0, then  $q$  and  $s$  are both 0 or both 1;

3. **3)** when G is




then p is 0 and R<sup>2</sup> is H, and the structure optionally includes a chelated metal ion;

4. **4)** when G is



and r is 0, then if p is 0, then one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>R<sup>2</sup>, and the other is H; and


5. **5)** when g is



then r is 0.

**[0058]** In some embodiments, Z is CO<sub>2</sub>Q. In some embodiments, Q is H. In some embodiments, m is 4, 5, or 6. In some embodiments, m is 6. In some embodiments, n is 2, 3, or 4. In some embodiments, n is 3. In some embodiments, a is 4. In some embodiments, subunits associated with elements p, q and s are in the order drawn and r may be in any location, including between one of p, q, or s. In some embodiments r is 0.

**[0059]** Embodiments include compounds having the structure



wherein:

Z is tetrazole or CO<sub>2</sub>Q;

each Q is independently selected from hydrogen or a protecting group;

a is 1, 2, 3, or 4;

R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

Ch is a metal chelating moiety optionally including a chelated metal, wherein Ch further includes any additional atoms or linkers necessary to attach the metal chelating moiety to the rest of the compound;

W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-;

Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O);

V is -C(O)-, -NRC(O)-, -NRC(S)-, or -OC(O)-;

m is 1, 2, 3, 4, 5, or 6;


n is 1, 2, 3, 4, 5 or 6;

p is 2;


R<sup>1</sup> is C<sub>2</sub>-C<sub>12</sub> aryl, wherein the aryl may be substituted or unsubstituted and R<sup>1</sup> may be the same or different;

R<sup>2</sup> and R<sup>3</sup> are independently H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>4</sup>, wherein R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl, wherein when one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>H or CO<sub>2</sub>R<sup>4</sup>, the other is H.

**[0060]** In some embodiments, the compound has the structure shown below.




**[0061]** In some embodiments, the compound has the structure shown below.




**[0062]** Each R<sup>1</sup> may be the same or different. When two R<sup>1</sup> groups are different, the two may be in any order. p is 2. In some embodiments, p is 2, and both R<sup>1</sup> are the same. In some embodiments, R<sup>1</sup> is C<sub>2</sub>-C<sub>12</sub> aryl. In some embodiments R<sup>1</sup> is phenyl. In some embodiments, R<sup>3</sup> is CO<sub>2</sub>H and R<sup>2</sup> is H. In some embodiments, R<sup>2</sup> is CO<sub>2</sub>H and R<sup>3</sup> is H. In some embodiments, R<sup>2</sup> and R<sup>3</sup> are both H.

**[0063]** Ch is a metal chelating moiety optionally including a chelated metal. A metal chelating moiety is a chemical moiety that non-covalently binds a metal atom, usually with a plurality of non-covalent interactions. Ch includes any additional atoms or linkers necessary to attach the metal chelating moiety to the rest of the compound. For instance linking groups having alkyl, aryl, combination of alkyl and aryl, or alkyl and aryl groups having heteroatoms may be present in the chelating moiety. Numerous metal chelating moieties are known in the art. Any


acceptable chelator can be used with the present invention as long as compatible and capable of chelating a desired metal. Examples of metal chelating moieties (Ch) include, but are not limited to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and Diethylenetriaminepentaacetic acid (DTPA). In some embodiments, Ch has a structure shown below.




[0064] Examples of specific compounds include the compounds shown below.





(not according to the invention)




(not according to the invention)




(not according to the invention)








(not according to the invention)




(not according to the invention)




(not according to the invention)





**[0065]** In some embodiments, the compound further includes a chelated metal. In some embodiments, the chelated metal is Tc, In, Ga, Y, Lu, Re, Cu, Ac, Bi, Pb, Sm, Sc, Co, Ho, Gd, Eu, Tb, or Dy. In some embodiments, the chelated metal is Tc, Ga, In, Cu, Y, Ac, Lu, Re, or Bi. In some embodiments the metal is an isotope, for example a radioactive isotope. In some embodiments, the isotope is Tc-99m, In-111, Ga-67, Ga-68, Y-86, Y-90, Lu-177, Re-186, Re-188, Cu-64, Cu-67, Co-55, Co-57, Sc-47, Ac-225, Bi-213, Bi-212, Pb-212, Sm-153, Ho-166, or Dy-166. In some embodiments, the isotope is Tc-99m, In-111, Ga-67, Ga-68, Y-90, Lu-177, Re-186, Re-188, Cu-67, Ac-225, Bi-213, or Bi-212.

**[0066]** Embodiments described in paragraphs [0092] to [00105] are part of the disclosure, but not part of the invention. Embodiments of the disclosure, but not part of the invention include compounds having the structure




optionally including a chelated metal ion. Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, and a is 1, 2, 3, or 4. R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-. Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O)-. In some embodiments, subunits associated with q and s may be in the order shown or the reverse thereof.

**[0067]** In exemplary embodiment of the disclosure, but not part of the invention m is 1, 2, 3, 4,


5, or 6; n is 1, 2, 3, 4, 5 or 6; q is 0 or 1; and s is 0 or 1.  $R^3$  is H,  $CO_2H$ , or  $CO_2R^4$ , where  $R^4$  is a  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_{12}$  aryl, or  $C_4$ - $C_{16}$  alkylaryl. Some embodiments further include a chelated metal ion. In some embodiments, the metal ion is Tc, Re, Ga, or Cu. In some embodiments, the metal ion is Tc-99m, Re-186, Re-188, Cu-64, or Ga-68. In some embodiments, the metal ion is Tc-99m, Re-186 or Re-188.

**[0068]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure




optionally including a chelated metal ion. Z is tetrazole or  $CO_2Q$ ; each Q is independently selected from hydrogen or a protecting group and a is 1, 2, 3, or 4. R is each independently H or  $C_1$ - $C_4$  alkyl. W is  $-NRC(O)-$ ,  $-NRC(O)NR-$ ,  $NRC(S)NR-$ ,  $-NRC(O)O-$ ,  $-OC(O)NR-$ ,  $-OC(O)-$ ,  $-C(O)NR-$ , or  $-C(O)O-$ . Y is  $-C(O)-$ ,  $-NRC(O)-$ ,  $-NRC(S)-$ ,  $-OC(O)-$ . In exemplary embodiments m is 1, 2, 3, 4, 5, or 6; and n is 1, 2, 3, 4, 5 or 6.  $R^3$  is H,  $CO_2H$ , or  $CO_2R^4$ , where  $R^4$  is a  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_{12}$  aryl, or  $C_4$ - $C_{16}$  alkylaryl.

**[0069]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure



where a is 1, 2, 3, or 4. Y is  $-C(O)-$ ,  $-NRC(O)-$ ,  $-NRC(S)-$ ,  $-OC(O)-$ , and In exemplary embodiment m is 1, 2, 3, 4, 5, or 6.


**[0070]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure



where a is 1, 2, 3, or 4. W is  $-NRC(O)-$ ,  $-NRC(O)NR-$ ,  $NRC(S)NR-$ ,  $-NRC(O)O-$ ,  $-OC(O)NR-$ , -

OC(O)-, -C(O)NR-, or -C(O)O-, and  $n$  is 1, 2, 3, 4, 5 or 6.  $R^3$  is H,  $\text{CO}_2\text{H}$ , or  $\text{CO}_2\text{R}^4$ , where  $\text{R}^4$  is a  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_2$ - $\text{C}_{12}$  aryl, or  $\text{C}_4$ - $\text{C}_{16}$  alkylaryl.

**[0071]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure



where  $a$  is 1, 2, 3, or 4.

**[0072]** In some embodiments,  $Y$  is  $-\text{C}(\text{O})-$ .


**[0073]** In some embodiments,  $W$  is  $-\text{NHC}(\text{O})-$ .

**[0074]** In some embodiments,  $m$  is 4, 5, or 6. In some embodiments,  $m$  is 6.

**[0075]** In some embodiments,  $n$  is 2, 3, or 4. In some embodiments,  $n$  is 3.


**[0076]** In some embodiments,  $\text{R}^3$  is  $\text{CO}_2\text{H}$ . In some embodiments,  $\text{R}^3$  is H. In some embodiments,  $\text{R}^3$  is  $\text{CO}_2\text{R}^4$ .


**[0077]** Examples of compounds of the disclosure, but not part of the invention include those having the structure shown below




**[0078]** In some embodiments, the compound further includes a chelated metal ion. In some embodiments, the metal ion is Tc, Re, Cu, or Ga. In some embodiments, the metal ion is Tc-99m, Re-186, Re-188, Cu-64, or Ga-68. In some embodiments, the metal ion is Tc-99m.

**[0079]** The metal ion chelates to the triazole amino acid portion of the molecule to form a structure shown below using Tc as an example.






**[0080]** Embodiments described in paragraphs [00106] to [00115] are part of the disclosure, but not part of the invention. Embodiments of the disclosure, but not part of the invention include compounds having the structure



where  $p$ ,  $q$ , and  $s$  are in the order drawn, and  $q$  and  $s$  are either both 0 or both 1.  $Z$  is tetrazole or  $\text{CO}_2\text{Q}$ ; each  $Q$  is independently selected from hydrogen or a protecting group, and  $a$  is 1, 2, 3, or 4.  $\text{FG}$  is a fluorescent dye moiety which emits in the visible or near infrared spectrum.  $R$  is each independently  $\text{H}$  or  $\text{C}_1\text{-C}_4$  alkyl.  $V$  is  $-\text{C}(\text{O})-$  or  $-\text{NRC}(\text{O})-$  or  $-\text{NRC}(\text{S})-$ .  $W$  is  $-\text{NRC}(\text{O})-$ ,  $-\text{NRC}(\text{O})\text{NR}-$ ,  $\text{NRC}(\text{S})\text{NR}-$ ,  $-\text{NRC}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{NR}-$ ,  $-\text{OC}(\text{O})-$ ,  $-\text{C}(\text{O})\text{NR}-$ , or  $-\text{C}(\text{O})\text{O}-$ .  $Y$  is  $-\text{C}(\text{O})-$ ,  $-\text{NRC}(\text{O})-$ ,  $-\text{NRC}(\text{S})-$ ,  $-\text{OC}(\text{O})$ . In exemplary embodiments  $m$  is 1, 2, 3, 4, 5, or 6;  $n$  is 1, 2, 3, 4, 5 or 6;  $p$  is 0, 1, 2, or 3, and when  $p$  is 2 or 3, each  $\text{R}^1$  may be the same or different.  $\text{R}^1$  is  $\text{H}$ ,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_2\text{-C}_{12}$  aryl, or  $\text{C}_4\text{-C}_{16}$  alkylaryl.  $\text{R}^2$  and  $\text{R}^3$  are independently  $\text{H}$ ,  $\text{CO}_2\text{H}$ , or  $\text{CO}_2\text{R}^2$ , where  $\text{R}^2$  is a  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_2\text{-C}_{12}$  aryl, or  $\text{C}_4\text{-C}_{16}$  alkylaryl, wherein when one of  $\text{R}^2$  and  $\text{R}^3$  is  $\text{CO}_2\text{H}$  or  $\text{CO}_2\text{R}^2$ , the other is  $\text{H}$ . In some embodiments, the fluorescent dye moiety emits in the near infrared spectrum.


**[0081]** Some embodiments of the disclosure, but not part of the invention have the structure shown below.




wherein  $Z$  is tetrazole or  $\text{CO}_2\text{Q}$ ; each  $Q$  is independently selected from hydrogen or a protecting group, and  $a$  is 1, 2, 3, or 4.  $\text{FG}$  is a fluorescent dye moiety which emits in the visible or near infrared spectrum.  $R$  is each independently  $\text{H}$  or  $\text{C}_1\text{-C}_4$  alkyl.  $V$  is  $-\text{C}(\text{O})-$  or  $-\text{NRC}(\text{O})-$  or  $-\text{NRC}(\text{S})-$ .  $W$  is  $-\text{NRC}(\text{O})-$ ,  $-\text{NRC}(\text{O})\text{NR}-$ ,  $\text{NRC}(\text{S})\text{NR}-$ ,  $-\text{NRC}(\text{O})\text{O}-$ ,  $-\text{OC}(\text{O})\text{NR}-$ ,  $-\text{OC}(\text{O})-$ ,  $-\text{C}(\text{O})\text{NR}-$ , or  $-\text{C}(\text{O})\text{O}-$ .  $Y$  is  $-\text{C}(\text{O})-$ ,  $-\text{NRC}(\text{O})-$ ,  $-\text{NRC}(\text{S})-$ ,  $-\text{OC}(\text{O})$ . In exemplary embodiments  $m$  is 1, 2, 3, 4, 5, or 6;  $n$  is 1, 2, 3, 4, 5 or 6;  $p$  is 0, 1, 2, or 3, and when  $p$  is 2 or 3, each  $\text{R}^1$  may be the same or different.  $\text{R}^1$  is  $\text{H}$ ,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_2\text{-C}_{12}$  aryl, or  $\text{C}_4\text{-C}_{16}$  alkylaryl.  $\text{R}^2$  and  $\text{R}^3$  are independently  $\text{H}$ ,  $\text{CO}_2\text{H}$ , or  $\text{CO}_2\text{R}^2$ , where  $\text{R}^2$  is a  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_2\text{-C}_{12}$  aryl, or  $\text{C}_4\text{-C}_{16}$  alkylaryl, wherein when one of  $\text{R}^2$  and  $\text{R}^3$  is  $\text{CO}_2\text{H}$  or  $\text{CO}_2\text{R}^2$ , the other is  $\text{H}$ . In some embodiments, the

fluorescent dye moiety emits in the near infrared spectrum.


**[0082]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure shown below.




**[0083]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure shown below.



**[0084]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure shown below.



**[0085]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure shown below.



**[0086]** In some embodiments, p is 1, 2 or 3. In some embodiments, p is 2. In some embodiments R<sup>1</sup> is C<sub>2</sub>-C<sub>12</sub> aryl. In some embodiments, R<sup>1</sup> is phenyl.

**[0087]** In some embodiments, p is 0.

**[0088]** In some embodiments, R<sup>3</sup> is CO<sub>2</sub>H and R<sup>2</sup> is H. In some embodiments, R<sup>2</sup> is CO<sub>2</sub>H and R<sup>3</sup> is H. In some embodiments, R<sup>2</sup> is CO<sub>2</sub>R<sup>4</sup>, and R<sup>3</sup> is H. In some embodiments, R<sup>3</sup> is CO<sub>2</sub>R<sup>4</sup>, and R<sup>2</sup> is H. In some embodiments R<sup>4</sup> is C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl. In some R<sup>4</sup> is benzyl.

In some embodiments, R<sup>2</sup> is H, and R<sup>3</sup> is H.

**[0089]** In some embodiments V is -C(O)- or -NRC(S)-.


**[0090]** FG is part of the disclosure, but not part of the invention. FG is a fluorescent dye moiety that emits light in the visible or near infrared spectrum. In some embodiments, FG is a fluorescent dye moiety which emits in the near infrared spectrum. FG includes any additional atoms or linkers necessary to attach the fluorescent dye moiety to the rest of the compound. For instance linking groups having alkyl, aryl, combination of alkyl and aryl, or alkyl and aryl groups having heteroatoms may be present in the chelating moiety, so long as the linker does not interfere with the fluorescence of the dye. In some embodiments, the fluorescent dye moiety includes a poly(ethyleneglycol) linker. Numerous fluorescent dye moieties are known in the art, and will be readily apparent to one of ordinary skill. Many fluorescent dyes are commercially available with activated groups used to react with protein sidechains or other compounds.








**[0091]** Examples of fluorescent compounds which may form all or part of the structure of FG include carbocyanine, indocarbocyanine, oxacarbocyanine, thiocarbocyanine, merocyanine, polymethine, coumarine, rhodamine, xanthene, fluorescein, and borondipyrromethane (BODIPY) compounds, to name a few.

**[0092]** Examples of fluorescent dye moieties include those described in WO 2008/109832.







**[0093]** Specific dyes which emit in the near infrared spectrum include commercially available compounds Cy5, Cy5.5, and Cy7, available from GE Healthcare; VivoTag-680, VivoTag-S680, and VivoTag-S750, available from VisEn Medical; AlexaFluor660, AlexaFluor680, AlexaFluor700, AlexaFluor750, and AlexaFluor790, available from Invitrogen; Dy677, Dy676, Dy682, Dy752, and Dy780, available from Dyonics; DyLight547, and Dylight647, available from Pierce; HiLyte Fluor 647, HiLyte Fluor 680, and HiLyte Fluor 750, available from AnaSpec; IRDye 800CW, IRDye 800RS, and IRDye 700DX, available from Li-Cor; and ADS780WS, ADS830WS, and ADS832WS, available from American Dye Source.


**[0094]** In some embodiments of the disclosure, but not part of the invention, FG is a structure shown below.













**[0096]** Embodiments described in paragraphs [00122] to [00134] are part of the disclosure, but not part of the invention. Embodiments of the disclosure, but not part of the invention include compounds having the structure




wherein Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4. One of A and A' is Ch and the other is FG, where FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum and Ch is metal chelating moiety optionally including a chelated metal. R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. V or V' are independently -C(O)-, -NRC(O)-, or -NRC(S)-. W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-. Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O)-. In exemplary embodiments m is 1, 2, 3, 4, 5, or 6; n is 1, 2, 3, 4, 5 or 6; and g is 1, 2, 3, 4, 5, or 6; p is 0, 1, 2, or 3, and when p is 2 or 3, each R<sup>1</sup> may be the same or

different.  $R^1$  is H,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_{12}$  aryl, or  $C_4$ - $C_{16}$  alkylaryl.  $R^2$  and  $R^3$  are independently H,  $CO_2H$ , or  $CO_2R^4$ , where  $R^4$  is a  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_{12}$  aryl, or  $C_4$ - $C_{16}$  alkylaryl, wherein when one of  $R'$  and  $R''$  is  $CO_2H$  or  $CO_2R^2$ , the other is H. In some embodiments, the fluorescent dye moiety emits in the near infrared spectrum. Some embodiments further include a chelated metal.


**[0097]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure shown below.




**[0098]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure shown below.



**[0099]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure shown below.



**[0100]** In some embodiments of the disclosure, but not part of the invention, the compound has the structure shown below.



**[0101]** In some embodiments,  $p$  is 1, 2 or 3. In some embodiments,  $p$  is 2. In some embodiments  $R^1$  is  $C_2$ - $C_{12}$  aryl. In some embodiments,  $R^1$  is phenyl.

[0102] In some embodiments, p is 0.


[0103] In some embodiments,  $R^3$  is  $\text{CO}_2\text{H}$  and  $R^2$  is H. In some embodiments,  $R^2$  is  $\text{CO}_2\text{H}$  and  $R^3$  is H. In some embodiments,  $R^2$  is  $\text{CO}_2\text{R}^4$ , and  $R^3$  is H. In some embodiments,  $R^3$  is  $\text{CO}_2\text{R}^4$ , and  $R^2$  is H. In some embodiments  $R^4$  is  $\text{C}_2\text{-C}_{12}$  aryl, or  $\text{C}_4\text{-C}_{16}$  alkylaryl. In some  $R^4$  is benzyl. In some embodiments,  $R^2$  is H, and  $R^3$  is H.

[0104] In some embodiments V and V' are individually  $-\text{C}(\text{O})-$  or  $-\text{NRC}(\text{S})-$ . This means that one of V and V' may be  $-\text{C}(\text{O})-$ , while the other is  $-\text{NRC}(\text{S})-$ , or that both V and V' are either  $-\text{C}(\text{O})-$  or  $-\text{NRC}(\text{S})-$ . V and V' will be determined, in part, on the type of FG and Ch used.

[0105] FG is a fluorescent dye moiety which emits light in the visible or near infrared spectrum. Exemplary fluorescent dye moieties are described previously.


[0106] Ch is a metal chelating group. Suitable metal chelating groups are described previously. In some embodiments, the compound further includes a chelated metal. The list of Exemplary metals and isotopes thereof are described previously.


[0107] Some embodiments of the disclosure, but not part of the invention have the structure




where FG and Ch are described previously, and each V is individually  $-\text{C}(\text{O})-$  or  $-\text{NRC}(\text{S})-$ .

[0108] Specific examples of compounds of the disclosure, but not part of the invention include the structures shown below.







**[0109]** Embodiments of the disclosure, but not part of the invention include compounds having the structure




wherein the subunits associated with elements p, q, r, and s may be in any order. Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, and a is 1, 2, 3, or 4. R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. In an exemplary embodiment r is 1. Tz is a triazole group having the structure




where L<sup>1</sup> is




L<sup>2</sup> is




or



X<sup>1</sup> is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, or -NRC(O)O-; X<sup>2</sup> is -C(O)NR-, -NRC(O)NR-, NRC(S)NR-, or -OC(O)NR-; R<sup>5</sup> is H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>6</sup>, where R<sup>6</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl; b is 1, 2, 3, or 4; and d is 1, 2, 3, or 4. In exemplary embodiments q is 0 or 1, W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-; n is 1, 2, 3, 4, 5 or 6; and R<sup>2</sup> and R<sup>3</sup> are independently H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>4</sup>, where R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl, wherein if one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>H or CO<sub>2</sub>R<sup>2</sup>, then the other is H. In exemplary embodiments s is 0 or 1; Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O); and m is 1, 2, 3, 4, 5, or 6. In exemplary embodiments p is 0, 1, 2, or 3, and when p is 2 or 3, each R<sup>1</sup> may be the same or different; and R<sup>1</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl. G<sup>1</sup> is a moiety selected from the group consisting of







where Ch is a metal chelating moiety, optionally including a chelated metal; FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum; one of A and A' is Ch and the other is FG; V and V' are each independently -C(O)-, -NRC(O)-, -NRC(S)-, or -OC(O)-; and g is 1, 2, 3, 4, 5, or 6. In some embodiments, the fluorescent dye moiety emits in the near infrared spectrum. Some embodiments include a chelated metal. In some embodiments the subunits associated with elements p, q, and s are in the order shown. In some embodiments, p is 0.

Embodiments described in paragraphs [00136] to [00146] are part of the disclosure, but not part of the invention.


**[0110]** Some embodiments of the disclosure, but not part of the invention have the structure shown below.



**[0111]** Some embodiments of the disclosure, but not part of the invention have the structure shown below.



**[0112]** Some embodiments of the disclosure, but not part of the invention have the structure shown below.



**[0113]** In some embodiments Y is -C(O)-. In some embodiments, W is -NRC(O)-.

**[0114]** In some embodiments, p is 1, 2 or 3. In some embodiments, p is 2. In some embodiments R<sup>1</sup> is C<sub>2</sub>-C<sub>12</sub> aryl. In some embodiments, R<sup>1</sup> is phenyl.

[0115] In some embodiments, p is 0.




[0116] In some embodiments,  $R^3$  is  $\text{CO}_2\text{H}$  and  $R^2$  is H. In some embodiments,  $R^2$  is  $\text{CO}_2\text{H}$  and  $R^3$  is H. In some embodiments,  $R^2$  is  $\text{CO}_2\text{R}^4$ , and  $R^3$  is H. In some embodiments,  $R^3$  is  $\text{CO}_2\text{R}^4$ , and  $R^2$  is H. In some embodiments  $R^4$  is  $\text{C}_2\text{-C}_{12}$  aryl, or  $\text{C}_4\text{-C}_{16}$  alkylaryl. In some  $R^4$  is benzyl. In some embodiments,  $R^2$  is H, and  $R^3$  is H.

[0117] In some embodiments, V and V' are individually  $-\text{C}(\text{O})-$  or  $-\text{NRC}(\text{S})-$ .


[0118] FG is a fluorescent dye moiety which emits light in the visible or near infrared spectrum. Exemplary fluorescent dye moieties are described previously and may be used in these embodiments.

[0119] Ch is a metal chelating group. Suitable metal chelating groups are described previously. In some embodiments, the compound further includes a chelated metal. The list of exemplary metals and isotopes thereof are described previously and may be used in these embodiments.

[0120] Examples of compounds include the structures shown below




[0121] Embodiments described in [00147] to [00153] are part of the disclosure, but not part of the invention. Embodiments also include intermediates used to make triazole compounds according to the various embodiments of the invention. Embodiments include compounds having the structure




wherein the subunits associated with elements p, q, r, and s may be in any order. Z is tetrazole or CO<sub>2</sub>Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4, and R is each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl. Variable q is 0 or 1. W is -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR-, or -C(O)O-; R<sup>2</sup> and R<sup>3</sup> are independently H, CO<sub>2</sub>H, or CO<sub>2</sub>R<sup>4</sup>, where R<sup>4</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl, wherein if one of R<sup>2</sup> and R<sup>3</sup> is CO<sub>2</sub>H or CO<sub>2</sub>R<sup>4</sup>, then the other is H; n is 1, 2, 3, 4, 5 or 6.

[0122] Variable s is 0 or 1. Y is -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O); and m is 1, 2, 3, 4, 5, or 6.


[0123] Variable p is 0, 1, 2, or 3, and when p is 2 or 3, each R<sup>1</sup> may be the same or different. R<sup>1</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>12</sub> aryl, or C<sub>4</sub>-C<sub>16</sub> alkylaryl. G<sup>2</sup> is -




[0124] In some embodiments, the compound has the structure shown below.




[0125] In some embodiments, the compound has the structure shown below.



[0126] In some embodiments, the compound has the structure shown below.



[0127] Examples include the compounds shown below.



[0128] Other embodiments of the disclosure, but not part of the invention include pharmaceutically acceptable salts of the compounds described in any of the previous embodiments. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making non-toxic acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic,  $\text{HOOC}-(\text{CH}_2)_n-\text{COOH}$  where  $n$  is 0-4, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used, where practicable. Lists of

additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, p. 1418 (1985).

### Preparation

**[0129]** The compounds described in the above embodiments may be made using procedures known in the art. In general, the materials used will be determined by the desired structure, and the type of linkage used.

**[0130]** Often, the compounds are prepared by sequentially adding components to a preformed urea, such as the lysine-urea-glutamate compounds described in Banerjee et al. (J. Med. Chem. vol. 51, pp. 4504-4517, 2008). Other urea-based compounds may also be used as building blocks.

**[0131]** Compounds are assembled by reactions between different components, to form linkages such as ureas (-NRC(O)NR-), thioureas (-NRC(S)NR-), amides (-C(O)NR- or -NRC(O)-), or esters (-C(O)O- or -OC(O)-). Urea linkages may be readily prepared by reaction between an amine and an isocyanate, or between an amine and an activated carbonamide (-NRC(O)-). Thioureas may be readily prepared from reaction of an amine with an isothiocyanate. Amides (-C(O)NR- or -NRC(O)-) may be readily prepared by reactions between amines and activated carboxylic acids or esters, such as an acyl halide or N-hydroxysuccinimide ester. Carboxylic acids may also be activated in situ, for example, with a coupling reagent, such as a carbodiimide, or carbonyldiimidazole (CDI). Esters may be formed by reaction between alcohols and activated carboxylic acids. Triazoles are readily prepared by reaction between an azide and an alkyne, optionally in the presence of a copper (Cu) catalyst.

**[0132]** Protecting groups may be used, if necessary, to protect reactive groups while the compounds are being assembled. Suitable protecting groups, and their removal, will be readily available to one of ordinary skill in the art.

**[0133]** In this way, the compounds may be easily prepared from individual building blocks, such as amines, carboxylic acids, and amino acids.

**[0134]** Often, a Ch or FB group is placed on the compound by adding a metal chelating group or fluorescent dye to the compound toward the end of a synthesis, for example by reacting a reactive amine on the compound with an activated metal chelating group or fluorescent dye. A wide variety of metal chelating groups and fluorescent dyes are known in the art, with activated functional groups for reacting with amines. The type of metal chelating group will be determined, in part by the desired metal. Selecting a metal chelating group for a particular metal atom will be apparent to one of ordinary skill in the art. The fluorescent dye used will be determined, in part, by the desired wavelength of fluorescence, and may be readily selected by one of ordinary skill in the art.

[0135] Exemplary procedures for specific compounds are described in the Examples below. Other compounds within the scope of the claims can be prepared using readily apparent modifications of these procedures.

### Uses

[0136] Compounds described above, including various radiolabeled compounds, may be used for diagnostic, imaging, or therapeutic purposes. In general, the suitability of a particular radioisotope for a particular purpose (i.e. imaging or therapeutic) is well understood in the art. Other exemplary embodiments are compounds used as precursors for radiolabeled compounds, in which a metal or radioactive isotope of a metal may be added to the compound. Some compounds according to the invention are intermediates for forming other compounds of the invention.

### Imaging

[0137] Embodiments include methods of imaging one or more cells, organs or tissues comprising exposing cells to or administering to a subject an effective amount of a compound with an isotopic label suitable for imaging. In some embodiments, the one or more organs or tissues include prostate tissue, kidney tissue, brain tissue, vascular tissue or tumor tissue. The cells, organs or tissues may be imaged while within an organism, either by whole body imaging or intraoperative imaging, or may be excised from the organism for imaging.

[0138] In another embodiment, the imaging method is suitable for imaging studies of PSMA inhibitors, for example, by studying competitive binding of non-radiolabeled inhibitors. In still another embodiment, the imaging method is suitable for imaging of cancer, tumor or neoplasm. In a further embodiment, the cancer is selected from eye or ocular cancer, rectal cancer, colon cancer, cervical cancer, prostate cancer, breast cancer and bladder cancer, oral cancer, benign and malignant tumors, stomach cancer, liver cancer, pancreatic cancer, lung cancer, corpus uteri, ovary cancer, prostate cancer, testicular cancer, renal cancer, brain cancer (e.g., gliomas), throat cancer, skin melanoma, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's Sarcoma, Kaposi's Sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, hemangioendothelioma, Wilms Tumor, neuroblastoma, mouth/pharynx cancer, esophageal cancer, larynx cancer, lymphoma, neurofibromatosis, tuberous sclerosis, hemangiomas, and lymphangiogenesis.

[0139] The imaging methods of the invention are suitable for imaging any physiological process or feature in which PSMA is involved. Typically, imaging methods are suitable for identification of areas of tissues or targets which express high concentrations of PSMA. Typical applications include imaging glutamateric neurotransmission, presynaptic glutamatergic

neurotransmission, malignant tumors or cancers that express PSMA, prostate cancer (including metastasized prostate cancer), and angiogenesis. Essentially all solid tumors express PSMA in the neovasculature. Therefore, methods of the present invention can be used to image nearly all solid tumors including lung, renal cell, glioblastoma, pancreas, bladder, sarcoma, melanoma, breast, colon, germ cell, pheochromocytoma, esophageal and stomach. Also, certain benign lesions and tissues including endometrium, schwannoma and Barrett's esophagus can be imaged according to the present invention.

**[0140]** The methods of imaging angiogenesis are suitable for use in imaging a variety of diseases and disorders in which angiogenesis takes place. Illustrative, non-limiting, examples include tumors, collagen vascular disease, cancer, stroke, vascular malformations, and retinopathy. Methods of imaging angiogenesis are also suitable for use in diagnosis and observation of normal tissue development.

**[0141]** PSMA is frequently expressed in endothelial cells of capillary vessels in peritumoral and endotumoral areas of various malignancies such that compounds of the invention and methods of imaging using same are suitable for imaging such malignancies.

**[0142]** In certain embodiments, the radiolabeled compound is stable *in vivo*.

**[0143]** In certain embodiments, the radiolabeled compound is detectable by positron emission tomography (PET) or single photon emission computed tomography (SPECT).

**[0144]** In some embodiments, the subject is a human, rat, mouse, cat, dog, horse, sheep, cow, monkey, avian, or amphibian. In another embodiment, the cell is *in vivo* or *in vitro*. Typical subjects to which compounds of the invention may be administered will be mammals, particularly primates, especially humans. For veterinary applications, a wide variety of subjects will be suitable, e. g. livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and domesticated animals particularly pets such as dogs and cats. For diagnostic or research applications, a wide variety of mammals will be suitable subjects including rodents (e.g. mice, rats, hamsters), rabbits, primates, and swine such as inbred pigs and the like. Additionally, for *in vitro* applications, such as *in vitro* diagnostic and research applications, body fluids and cell samples of the above subjects will be suitable for use such as mammalian, particularly primate such as human, blood, urine or tissue samples, or blood urine or tissue samples of the animals mentioned for veterinary applications. In other *in vitro* applications, the cells or tissues are present in culture or in suspension.

**[0145]** Imaging agents of the invention may be used in accordance with the methods disclosed herein by one of skill in the art. Images can be generated by virtue of differences in the spatial distribution of the imaging agents which accumulate at a site when contacted with PSMA. The spatial distribution may be measured using any means suitable for the particular label, for example, a gamma camera, a PET apparatus, a SPECT apparatus, a fluorescence camera and the like. The extent of accumulation of the imaging agent may be quantified using known

methods for quantifying radioactive emissions. A particularly useful imaging approach employs more than one imaging agent, or a bimodal agent having a fluorescent dye moiety and a metal chelating group, such as those described above, to perform simultaneous studies.

**[0146]** In general, a detectably effective amount of the imaging agent is administered to a subject. As used herein, "a detectably effective amount" of the imaging agent is defined as an amount sufficient to yield an acceptable image using equipment which is available for clinical use. A detectably effective amount of the imaging agent may be administered in more than one injection. The detectably effective amount of the imaging agent can vary according to factors such as the degree of susceptibility of the individual, the age, sex, and weight of the individual, idiosyncratic responses of the individual, and the dosimetry. Detectably effective amounts of the imaging agent can also vary according to instrument and film-related factors. Optimization of such factors is well within the level of skill in the art. The amount of imaging agent used for diagnostic purposes and the duration of the imaging study will depend upon the radionuclide used to label the agent, the body mass of the patient, the nature and severity of the condition being treated, the nature of therapeutic treatments which the patient has undergone, and on the idiosyncratic responses of the patient. Ultimately, the attending physician will decide the amount of imaging agent to administer to each individual patient and the duration of the imaging study.

**[0147]** In some embodiments, the compounds are excreted from tissues of the body quickly to prevent prolonged exposure to the radiation of the radiolabeled compound administered to the patient. Generally, the compounds are excreted from tissues of the body slowly enough to allow sufficient time for imaging or other use. Typically compounds of the invention are eliminated from the body in less than about 24 hours. More typically, compounds of the invention are eliminated from the body in less than about 16 hours, 12 hours, 8 hours, 6 hours, 4 hours, 2 hours, 90 minutes, or 60 minutes. Exemplary compounds are eliminated in between about 60 minutes and about 120 minutes.

**[0148]** In some embodiments of the invention, the compounds are designed to increase uptake in PSMA positive cells (i.e. tumor cells). For example, highly hydrophilic compounds may be excreted quickly. Compounds with increased hydrophobicity, such as compounds having hydrophobic linkers, may have longer circulation times, thereby providing more prolonged supply of tracer to bind to cells. According to embodiments of compounds according to the invention, hydrophobicity can be increased when, for example,  $p$  is 1 or more, or when  $R^2$  or  $R^3$  is  $CO_2R^4$

### **Therapeutic Uses**

**[0149]** Embodiments of the invention include methods of treating a tumor comprising administering a therapeutically effective amount of a compound discussed above, where the compound includes a therapeutically effective radioisotope. The development of low molecular

weight radiotherapeutic agents is much different from developing radiopharmaceuticals for imaging in that longer tumor residence times may be important for the former.

**[0150]** In some embodiments, the tumor cells may express PSMA, such as prostate tumor cells or metastasized prostate tumor cells. In other embodiments, a tumor may be treated by targeting adjacent or nearby cells which express PSMA. For example, vascular cells undergoing angiogenesis associated with a tumor may be targeted. Essentially all solid tumors express PSMA in the neovasculature. Therefore, methods of the present invention can be used to treat nearly all solid tumors including lung, renal cell, glioblastoma, pancreas, bladder, sarcoma, melanoma, breast, colon, germ cell, pheochromocytoma, esophageal and stomach. Also, certain benign lesions and tissues including endometrium, schwannoma and Barrett's esophagus can be treated according to the present invention. Examples of therapeutically effective radioisotopes include  $^{90}\text{Y}$ ,  $^{177}\text{Lu}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{67}\text{Cu}$ ,  $^{225}\text{Ac}$ ,  $^{213}\text{Bi}$ ,  $^{212}\text{Bi}$ ,  $^{67}\text{Ga}$ ,  $^{111}\text{In}$ ,  $^{153}\text{Sm}$ ,  $^{212}\text{Pb}$ ,  $^{131}\text{I}$  and  $^{211}\text{At}$ .

### **Cell Sorting**

**[0151]** Embodiments of the disclosure, but not part of the invention include methods for sorting cells by exposing the cells to a compound discussed above, where the compound includes a fluorescent dye moiety, followed by separating cells which bind the compound from cells which do not bind the compound.

**[0152]** Fluorescent compounds described above bind to PSMA on cells that express PSMA on the cell surface. In some cases, fluorescent compound is internalized. Cells binding the fluorescent compound appear fluorescent, and may be imaged using fluorescence microscopy. Fluorescence-activated cell sorting (FACS) or flow cytometry may be used to separate PSMA positive cells from PSMA negative cells.

### **Intraoperative Tumor Mapping**

**[0153]** Embodiments of the disclosure, but not part of the invention include methods of intraoperative tumor mapping or intraoperative photodiagnosis (PDD) by administering an effective amount of a compound discussed above to a subject, where the compound includes a fluorescent dye moiety. According to such embodiments, an effective amount of a compound is an amount sufficient to produce a detectable level of fluorescence when used for intraoperative tumor mapping or PDD. The compounds bind to, and may be internalized into, cells, particularly tumor cells, that express PSMA. The fluorescent compounds thereby define the boundaries of the tumor, allowing for accurate surgical removal. The compounds that includes a fluorescent dye moiety may also be used to visualize circulating tumor cells that express PSMA.

### Pharmaceutical Compositions and Kits

**[0154]** The compounds discussed herein can be formulated into various compositions, for use in diagnostic, imaging or therapeutic treatment methods. The compositions (e.g. pharmaceutical compositions) can be assembled as a kit. Generally, a pharmaceutical composition comprises an effective amount (e.g., a pharmaceutically effective amount, or detectably effective amount) of a compound described above.

**[0155]** A composition of the invention can be formulated as a pharmaceutical composition, which comprises a compound of the invention and pharmaceutically acceptable carrier. By a "pharmaceutically acceptable carrier" is meant a material that is not biologically or otherwise undesirable, *i.e.*, the material may be administered to a subject without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art. For a discussion of pharmaceutically acceptable carriers and other components of pharmaceutical compositions, see, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, 1990. Some suitable pharmaceutical carriers will be evident to a skilled worker and include, e.g., water (including sterile and/or deionized water), suitable buffers (such as PBS), physiological saline, cell culture medium (such as DMEM), artificial cerebral spinal fluid, or the like.

**[0156]** A pharmaceutical composition or kit of the invention can contain other pharmaceuticals, in addition to the compound. The other agent(s) can be administered at any suitable time during the treatment of the patient, either concurrently or sequentially.

**[0157]** One skilled in the art will appreciate that the particular formulation will depend, in part, upon the particular agent that is employed, and the chosen route of administration. Accordingly, there is a wide variety of suitable formulations of compositions of the present invention.

**[0158]** One skilled in the art will appreciate that a suitable or appropriate formulation can be selected, adapted or developed based upon the particular application at hand. Dosages for compositions of the invention can be in unit dosage form. The term "unit dosage form" as used herein refers to physically discrete units suitable as unitary dosages for animal (e.g. human) subjects, each unit containing a predetermined quantity of an agent of the invention, alone or in combination with other therapeutic agents, calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier, or vehicle.

**[0159]** One skilled in the art can easily determine the appropriate dose, schedule, and method of administration for the exact formulation of the composition being used, in order to achieve

the desired effective amount or effective concentration of the agent in the individual patient.

**[0160]** The dose of a composition of the invention, administered to an animal, particularly a human, in the context of the present invention should be sufficient to produce at least a detectable amount of a diagnostic or therapeutic response in the individual over a reasonable time frame. The dose used to achieve a desired effect will be determined by a variety of factors, including the potency of the particular agent being administered, the pharmacodynamics associated with the agent in the host, the severity of the disease state of infected individuals, other medications being administered to the subject, etc. The size of the dose also will be determined by the existence of any adverse side effects that may accompany the particular agent, or composition thereof, employed. It is generally desirable, whenever possible, to keep adverse side effects to a minimum. The dose of the biologically active material will vary; suitable amounts for each particular agent will be evident to a skilled worker.

**[0161]** Other embodiments provide kits including a compound according to the invention. In certain embodiments, the kit provides packaged pharmaceutical compositions having a pharmaceutically acceptable carrier and a compound of the invention. In some embodiments the packaged pharmaceutical composition will include the reaction precursors necessary to generate the compound of the invention upon combination with a radionuclide. Other packaged pharmaceutical compositions provided by the present invention further comprise indicia comprising at least one of: instructions for preparing compounds according to the invention from supplied precursors, instructions for using the composition to image cells or tissues expressing PSMA, or instructions for using the composition to image glutamatergic neurotransmission in a patient suffering from a stress-related disorder, or instructions for using the composition to image prostate cancer.

**[0162]** In certain embodiments, a kit according to the invention contains from about 1 mCi to about 30 mCi of the radionuclide-labeled imaging agent described above, in combination with a pharmaceutically acceptable carrier. The imaging agent and carrier may be provided in solution or in lyophilized form. When the imaging agent and carrier of the kit are in lyophilized form, the kit may optionally contain a sterile and physiologically acceptable reconstitution medium such as water, saline, buffered saline, and the like. The kit may provide a compound of the invention in solution or in lyophilized form, and these components of the kit of the invention may optionally contain stabilizers such as NaCl, silicate, phosphate buffers, ascorbic acid, gentisic acid, and the like. Additional stabilization of kit components may be provided in this embodiment, for example, by providing the reducing agent in an oxidation-resistant form. Determination and optimization of such stabilizers and stabilization methods are well within the level of skill in the art.

**[0163]** A "pharmaceutically acceptable carrier" refers to a biocompatible solution, having due regard to sterility, p[Eta], isotonicity, stability, and the like and can include any and all solvents, diluents (including sterile saline, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection and other aqueous buffer solutions), dispersion media, coatings, antibacterial and antifungal agents,

isotonic agents, and the like. The pharmaceutically acceptable carrier may also contain stabilizers, preservatives, antioxidants, or other additives, which are well known to one of skill in the art, or other vehicle as known in the art.

**[0164]** The invention and the manner and process of making and using it, are described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same.

**[0165]** While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. It is intended, therefore, that the invention be defined by the scope of the claims that follow and that such claims be interpreted as broadly as is reasonable.


**[0166]** It is to be understood that the foregoing describes exemplary embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the appended claims.


## EXAMPLES

**[0167]** The present invention is further illustrated by the following examples which should not be construed as limiting in any way. The practice of the present invention will employ, unless otherwise indicated, conventional techniques, which are within the skill of the art. Such techniques are explained fully in the literature.

### EXAMPLE 1 (not according to the invention)

**[0168]** 2-{3-[5-(7-{5-[4-(2-Amino-2-carboxy-ethyl)-[1,2,3]triazol-1-yl]-1-carboxy-pentylcarbamoyl]-heptanoylamino)-1-carboxy-pentyl]-ureido}-pentanedioic acid, compound SRV32. The compound SRV32 was prepared in three steps following the scheme shown below.





1. a TEA, DMF, 16h, rt; b.  $\text{Cu}(\text{OAc})_2$ , Sodium ascorbate, water/t-BuOH(1:1), rt, 18 h;
2. b.  $\text{Cu}(\text{OAc})_2$ , Na-ascorbate,  $\text{H}_2\text{O}$ , rt, 12 h;
3. c. TFA/ $\text{CH}_2\text{Cl}_2$ (1:1), 16 h, rt.

**[0169]** The compound 1 was prepared from literature method (Banerjee et al., J Med Chem, vol. 51, pp. 4504-4517, 2008). To a solution of compound 1 (100mg, 0.107 mmol in 5 ml DMF) was added H-Lys( $\epsilon$ -azide)-OH (20 mg, 0.107mmol) (Boc-Lys(Azide)-OH was purchased from Anaspec. The removal of Boc group was done by treating the commercial compound with 1:1 TFA: $\text{CH}_2\text{Cl}_2$  at room temperature for 4 hr, and the solution was stirred for 16h at rt. The solvent was removed under vacuum. The solid residue thus obtained was dissolved in 10 ml ethyl acetate and extracted with  $3 \times 10$  mL water. Organic layer was dried under vacuum to get a colorless solid as the protected azido urea compound SRV25. ESIMS: 991[M+1]<sup>+</sup>. To the Compound SRV25(60 mg, 0.06 mmol in 1 ml t-BuOH), was added N(a)-Boc-L-propargylglycine(Anaspec) (14 mg, 0.012 mmol in 1 ml t-BuOH), followed by  $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$  (2 mg, 0.012 mmol in 1 ml water) and sodium ascorbate (4.75 mg, 0.024 mmol in 1 ml water) and the mixture stirred at room temperature for 12 h. The product was extracted into  $\text{CH}_2\text{Cl}_2$  and washed twice with aqueous NaCl. The aqueous phases were re-extracted with  $\text{CH}_2\text{Cl}_2$ . The organic phases were combined, dried over  $\text{Na}_2\text{SO}_4$  and evaporated. The product, compound SRV29, was purified by a silica gel pipette column eluted with solution of 90/10  $\text{CH}_2\text{Cl}_2$ / MeOH. ESIMS: Calcd for  $\text{C}_{60}\text{H}_{82}\text{N}_8\text{O}_{18}$  1203.57, found 1204[M+1]<sup>+</sup>.

**[0170]** The compound SRV29 was dissolved in 2 ml 1/1  $\text{CHCl}_3$ /TFA and stirred overnight. The solution was removed under vacuum to get a colorless solid. The solid was washed 3 times with 5 ml  $\text{CH}_2\text{Cl}_2$  to remove impurities. The crude solid, compound SRV32 was further purified by HPLC using a 85/15 water/ acetonitrile (0.1% TFA in each) flow rate 4 ml,  $R_t=10.2$  min.

ESMS: 742.77[M+1]<sup>+</sup>, <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$ : 7.46(M, 1H), 5.2(m, 2H) 4.35(m, 1H), 4.26(m, 1H), 4.18(m, 1H), 3.80-3.70(m, 1H), 3.18(t, *J* = 6 Hz, 2H), 2.69(m, 2H), 2.51(t, *J* = 7.6 Hz, 2H), 2.40-2.18(m, 25H).

[0171] Radiolabeling with Tc-99m was performed by the same procedure described previously (Banerjee et al., J Med Chem, vol. 51, pp. 4504-4517, 2008).

### **Biodistribution and Imaging**

[0172] A single SCID mouse implanted with both a PC-3 PIP (PSMA+) and a PC-3 flu (PSMA-) xenograft was injected intravenously with compound <sup>99m</sup>Tc-SRV32 in saline. At 0.5 hr, 1 hr, 2 h, and 5 h p.i. the mouse was anesthetized with isoflurane and maintained under 1% isoflurane in oxygen. The mouse was positioned on the X-SPECT (Gamma Medica, Northridge, CA) gantry and was scanned using two low energy, high-resolution pinhole collimators (Gamma Medica) rotating through 360° in 6° increments for 45 seconds per increment. All gamma images were reconstructed using Lunagem software (Gamma Medica, Northridge, CA). Immediately following SPECT acquisition, the mice were then scanned by CT (X-SPECT) over a 4.6 cm field-of-view using a 600  $\mu$ A, 50 kV beam. The SPECT and CT data were then coregistered using the supplier's software (Gamma Medica, Northridge, CA) and displayed using AMIDE (<http://amide.sourceforge.net/>). Data were reconstructed using the Ordered Subsets-Expectation Maximization (OS-EM) algorithm.


[0173] Tissue biodistribution was measured. Results are summarized in the following table. <sup>99m</sup>Tc-SRV32 exhibited high uptake (~7% ID/g at 30 minutes), and good clearance from non-target tissues.

<b>Tissue</b>	<b>30 min</b>	<b>60 min</b>	<b>120 min</b>	<b>300 min</b>
blood	1.38 $\pm$ 0.4	0.63 $\pm$ 0.1	0.61 $\pm$ 0.3	0.19 $\pm$ 0.1
liver	14.26 $\pm$ 1.0	9.81 $\pm$ 2.0	5.65 $\pm$ 0.5	3.06 $\pm$ 0.6
stomach	0.77 $\pm$ 0.1	0.42 $\pm$ 0.09	0.29 $\pm$ 0.1	0.18 $\pm$ 0.1
spleen	26.10 $\pm$ 9.0	17.31 $\pm$ 6.6	5.80 $\pm$ 1.9	1.26 $\pm$ 0.5
kidney	139.53 $\pm$ 17.2	144.65 $\pm$ 15.1	151.23 $\pm$ 37.1	80.00 $\pm$ 8.4
muscle	0.56 $\pm$ 0.1	0.40 $\pm$ 0.2	0.16 $\pm$ 0.1	0.51 $\pm$ 0.6
small intestine	1.94 $\pm$ 1.1	0.74 $\pm$ 0.3	0.39 $\pm$ 0.2	0.26 $\pm$ 0.2
large intestine	0.61 $\pm$ 0.1	0.36 $\pm$ 0.1	0.53 $\pm$ 0.4	2.96 $\pm$ 1.3
bladder	1.07 $\pm$ 0.1	3.09 $\pm$ 2.6	5.39 $\pm$ 7.1	2.74 $\pm$ 2.1
PC-3 PIP	6.67 $\pm$ 1.6	5.32 $\pm$ 1.2	3.77 $\pm$ 0.8	2.19 $\pm$ 0.5
PC-3 flu	0.75 $\pm$ 0.2	0.45 $\pm$ 0.3	0.35 $\pm$ 0.2	0.43 $\pm$ 0.4

**[0174]** A single SCID mouse implanted with a PSMA+ LnCaP xenograft was injected intravenously with compound  $^{99m}\text{Tc}$ -SRV32 in saline. At 0.5 hr, and 3.5 hr p.i. the mouse was anesthetized with isoflurane and maintained under 1% isoflurane in oxygen. The mouse was positioned on the X-SPECT (Gamma Medica, Northridge, CA) gantry and was scanned using two low energy, high-resolution pinhole collimators (Gamma Medica) rotating through  $360^\circ$  in  $6^\circ$  increments for 45 seconds per increment. All gamma images were reconstructed using Lunagem software (Gamma Medica, Northridge, CA). Immediately following SPECT acquisition, the mice were scanned by CT (X-SPECT) over a 4.6 cm field-of-view using a  $600\ \mu\text{A}$ , 50 kV beam. The SPECT and CT data were then coregistered using the supplier's software (Gamma Medica, Northridge, CA) and displayed using AMIDE (<http://amide.sourceforge.net/>). Data were reconstructed using the Ordered Subsets-Expectation Maximization (OS-EM) algorithm. Images are shown in **Figure 1**.

### COMPARATIVE EXAMPLE 1

**[0175]** Under the same conditions, tumor uptake for compound  $^{99m}\text{Tc}$ -L1, shown below, was determined. Results are summarized in the following table. The data show that while  $^{99m}\text{Tc}$ -L1 shows good retention, compound  $^{99m}\text{Tc}$ -SRV32 has greater retention *in vivo* both for target tumor and nontarget tissues, and lower GI uptake than the previous  $^{99m}\text{Tc}$ -L1 compound at initial time points.



Tissue	30 min	60 min	120 min	300 min
PC-3 PIP	$7.9 \pm 4$	$3.9 \pm 0.6$	$2.0 \pm 0.8$	$0.8 \pm 0.5$
PC-3 flu	$0.3 \pm 0.2$	$0.2 \pm 0.1$	$0.05 \pm 0.02$	$0.01 \pm 0.01$

### EXAMPLE 2 - $^{68}\text{Ga}$ Compounds

#### General

**[0176]** Solvents and chemicals obtained from commercial sources were of analytical grade or better and used without further purification. All experiments were performed in duplicate or

triplicate to ensure reproducibility. Analytical thin-layer chromatography (TLC) was performed using Aldrich aluminum-backed 0.2 mm silica gel Z19, 329-1 plates and visualized by ultraviolet light (254 nm), 12 and 1% ninhydrin in EtOH. Flash chromatography was performed using silica gel purchased from Bodman (Aston PA), MP SiliTech 32-63 D 60Å. <sup>1</sup>H NMR spectra were recorded on either a Varian Mercury 400 MHz or on a Bruker ultrashield™ 400 MHz spectrometer. Chemical shifts (δ) are reported in ppm downfield by reference to proton resonances resulting from incomplete deuteration of the NMR solvent. Low resolution ESI mass spectra were obtained on a Bruker Daltonics Esquire 3000 Plus spectrometer. Higher-resolution FAB mass spectra were obtained on a JOEL JMS-AX505HA mass spectrometer in the mass spectrometer facility at the University of Notre Dame. Optical rotation was measured on a Jasco P-1010 polarimeter. Infrared spectra were obtained on a Bruker Tensor 27 spectrometer. High-performance liquid chromatography (HPLC) purification of new compounds was performed using a Phenomenex C<sub>18</sub> Luna 10 × 250 mm<sup>2</sup> column on a Waters 600E Delta LC system with a Waters 486 tunable absorbance UV/Vis detector, both controlled by Empower software.

**[0177]** For purification of radiolabeled [<sup>68</sup>Ga]SRV100, a Varian Microsorb-Mv C<sub>18</sub> 250 × 4.6mm<sup>2</sup> column was used. HPLC was performed using the following isocratic conditions: For Method 1, the mobile phase was 80% solvent A (0.1% TFA in water) and 20% solvent B (0.1% TFA in CH<sub>3</sub>CN), flow rate 4 mL/min; for Method 2, the mobile phase was 80% solvent A and 20% solvent B, flow rate 1 mL/min. Method 1 was used for purification of compounds SRV27, [<sup>69/71</sup>Ga]SRV27, SRV100, [<sup>69/71</sup>Ga]SRV100 and [<sup>68</sup>Ga]SRV27.

**[0178]** For purification of [<sup>68</sup>Ga]SRV100 Method 2 was used. For radiosynthetic purification, HPLC was performed on a Varian Prostar System (Palo Alto, CA), equipped with a model 490 UV absorbance detector and a Bioscan NaI scintillation detector connected to a Bioscan Flow-count system controlled by Empower software.

### **Radiochemistry**

**[0179]** <sup>68</sup>Ga labeling protocol for compound SRV27 was done following a literature procedure (Zhernosekov et al., J Nucl Med, vol. 48, pp. 1741-1748, 2007). A detailed description is given below.

1. 13.2mCi of <sup>68</sup>Ga in 7 mL of 0.1N HCl were obtained from more than 1-year-old 740-MBq generator. The solution was transferred on a cation-exchange cartridge, Phenomenex Strata-X-C tubes (33µm strong cation exchange resin, part no. 8B-S029-TAK, 30 mg/1ml).
2. The column was eluted with 5 ml of a solution of 20/80 0.10N hydrochloric acid/acetone. The eluant remaining on the cation-exchanger was removed by passage of nitrogen. These two processes aimed to remove most of the remaining chemical and

radiochemical impurities from the resin, whereas  $^{68}\text{Ga}(\text{III})$  should quantitatively remain on the column.

3. 3. The column was filled with 150  $\mu\text{L}$  of a 2.4/97.6 0.05N HCl/acetone solution. About 2 min standing appeared to be best for complete desorption of the  $^{68}\text{Ga}(\text{III})$  from the resin into the liquid phase. An additional 250  $\mu\text{L}$  of this mixture were applied, and the purified  $^{68}\text{Ga}(\text{III})$  was obtained in 400  $\mu\text{L}$  of this eluent overall.
4. 4. The fraction (400  $\mu\text{L}$  eluent) was used directly for the labeling of DOTA-urea compound. The processed activity was added to 500  $\mu\text{L}$  pure  $\text{H}_2\text{O}$  in a standard glass reagent vial containing 100 $\mu\text{l}$  (92 nmol, 1 mg/mL solution) of ligand. No buffer solution was added. The reaction vial was heated at  $95^\circ\text{C}$  for 10 min. The complexation was monitored by injecting aliquots of 100  $\mu\text{l}$  (210  $\mu\text{Ci}$ ) of the solution in HPLC. Product obtained =160  $\mu\text{Ci}$ . Radiochemical Yield= $(160/210)\times 100=76.19\%$  (without decay correction). Solvent system 80/20 water/acetonitrile (0.1% TFA in each),  $R_t$  (retention time) =25 min for the compound and  $R_t=19$  min for the free ligand. Product obtained = 5.92 MBq. For  $[^{68}\text{Ga}]\text{SRV27}$ , radiochemical yield: 76.2% (without decay correction). HPLC was performed by Method 1 as described in the General experimental section.  $R_t$  = 25 min for the desired product and  $R_t$  = 19 min for the free ligand. For  $[^{68}\text{Ga}]\text{SRV100}$ , radiochemical yield: 70%. HPLC was performed by Method 2 as mentioned in General experimental section.  $R_t$  = 22.5 min for the desired product and  $R_t$  = 16 min for the free ligand.


### **Cell Lines and Tumor Models**

**[0180]** PC-3 PIP (PSMA+) and PC-3 flu (PSMA<sup>-</sup>) cell lines were obtained from Dr. Warren Heston (Cleveland Clinic) and were maintained as previously described (Mease et al., Clin Cancer Res, vol. 14, pp. 3036-3043, 2008). LNCaP cells were obtained from American Type Culture Collection (ATCC, Manassas, VA) and were maintained as per ATCC guidelines. All cells were grown to 80-90% confluence before trypsinization and formulation in Hank's Balanced Salt Solution (HBSS, Sigma, St. Louis, MO) for implantation into mice.

**[0181]** Animal studies were undertaken in compliance with institutional guidelines related to the conduct of animal experiments. For biodistribution studies of  $[^{68}\text{Ga}]\text{SRV27}$ , and  $[^{68}\text{Ga}]\text{SRV100}$  and imaging studies of  $[^{68}\text{Ga}]\text{SRV100}$ , male SCID mice (NCI) were implanted subcutaneously with  $1 - 5 \times 10^6$  PSMA+ PC-3 PIP and PSMA- PC-3 flu cells behind either shoulder. For imaging studies of  $[^{68}\text{Ga}]\text{SRV27}$ , male SCID mice (NCI) were implanted subcutaneously with  $5 \times 10^6$  LNCaP cells behind the right shoulder. Mice were imaged or used in biodistribution studies when the tumor xenografts reached 3-5 mm in diameter.

### **Synthesis of SRV27 (not according to the invention)**

**[0182]** 2-{3-[5-(7-{1-Benzyloxycarbonyl-5-[2-(4,7,10-tris-carboxymethyl-1,4,7,10tetraazacyclododec-1-yl)-acetylamino]-pentylcarbamoyl}-heptanoylamino)-1-carboxy-pentyl]-ureido}-pentanedioic acid (**SRV27**). Compound **SRV27** was prepared in three steps according to the following scheme.



**[0183]** Compound **1** was prepared according to a literature method (Banerjee et al., J Med Chem, vol. 51, pp. 4504-4517, 2008). To a solution of compound **1** (100 mg, 0.11 mmol in 5 mL DMF) was added H-Lys(Boc)-OBz (36 mg, 0.11 mmol) (Hamachi et al., Chem. Eur. J., vol. 5, pp. 1503-1511, 1999). The solution was stirred for 16 h at ambient temperature. The solvent was removed under vacuum. The solid residue thus obtained was dissolved in 10 mL ethyl acetate and extracted with  $3 \times 10$  mL water. The organic layer was dried under vacuum to provide a colorless solid ESIMS: 1154  $[\text{M}+1]^+$ . This crude compound was dissolved in 3 mL  $\text{CHCl}_3$  followed by addition of 3 mL TFA at  $0^\circ\text{C}$ . The solution was allowed to stir overnight at ambient temperature. The volume of the solution was reduced under vacuum and the solid residue was washed with  $3 \times 5$  mL  $\text{CH}_2\text{Cl}_2$  to remove impurities. The colorless solid residue, **3**, was dried under vacuum to give 80 mg of compound **3**. Compound **3** was purified further by using a 2 g Sep Pak  $\text{C}_{18}$  cartridge with a solution of 85/15 water/acetonitrile (0.1% TFA in each).  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ ,  $\delta$ ): 7.5 (bm, 5H), 4.27 (m, 1H), 4.12 (m, 1H), 3.99 (m, 1H), 3.04 (m, 4H), 2.38 (m, 2H), 2.3-1.0 (m, 27H). ESIMS: 694  $[\text{M}+1]^+$ . To a solution of DOTA-mono-NHS (54 mg, 0.11 mmol in 5 mL DMF) was added **3** (80mg, 0.08 mmol) and TEA (60  $\mu\text{L}$ , 0.43 mmol) and the solution was allowed to stir for 16 h at ambient temperature. Solvent was removed under vacuum and the crude solid, **SRV27**, was purified by HPLC Method 1, retention time 19 min.

Yield: ~ 40%. ESMS: 1080[M+1]<sup>+</sup>, HRESI<sup>+</sup>- MS: Calcd. for C<sub>49</sub>H<sub>77</sub>N<sub>9</sub>O<sub>18</sub>, 1080.5487 [M+H], found: 1080.5459. <sup>1</sup>H NMR (D<sub>2</sub>O) δ: 7.88 (m, 4H), 4.26-4.1 (m, 5H), 3.45-3.18 (m, 16H), 2.52-2.43 (m, 16H), 2.40-2.18 (m, 25H). <sup>13</sup>C (CD<sub>3</sub>CO<sub>2</sub>D) d: 177.5, 177.6, 175.3, 172.3, 160.6, 160.2, 159.8, 159.5, 135.5, 128.5, 128.4, 119.9, 117, 114.0, 111.3, 67.3, 55.5, 53.1, 51.0, 49.9, 30.7, 28.0, 26.4, 25.1.

**[0184] 2-[3-[5-(7-{1-Benzoyloxycarbonyl-5-[2-(4,7,10-tris-carboxymethyl-1,4,7,10tetraaza-cyclododec-1-yl)-acetylamino]-pentylcarbamoyl]-heptanoylamino)-1-carboxy-pentyl]-ureido]-pentanedioic acid Gallium (III), SRV31 ([<sup>69/71</sup>Ga]-SRV27).** To a solution of GaNO<sub>3</sub> (10 mg, 39μmol) in deionized water was added compound SRV27(4.2mg, 39μmol) in 1 mL deionized water and the resulting solution was heated in boiling water for 10 min. The solvent was evaporated to dryness and the crude residue was purified by HPLC using a 80/20 water/acetonitrile (0.1% TFA in each), flow rate 8 ml/min. Retention time for the product was at 12 min. Yield:-35% ESMS: 1146[M+1]<sup>+</sup>, <sup>1</sup>H NMR (D<sub>2</sub>O) δ: 7.88 (m, 4H), 4.26-4.1 (m, 5H), 3.45 (m, 8H) 3.18 (m, 8H), 2.69 (m, 8H), 2.51 (m, 8H), 2.40-2.18 (m, 25H).

### SRV100

**[0185] 2-[3-(1-Carboxy-5-[7-[5-carboxy-5-(3-phenyl-2-{3-phenyl-2-[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetylamino]-propionylamino]-propionylamino)-pentylcarbamoyl]-heptanoylamino)-pentyl]-ureido]-pentanedioic acid, (SRV100).** Compound SRV100 was prepared according to the scheme shown in **Figure 4**. Fmoc-Lys(Boc)-Wang resin (100 mg, 0.43 mM) was allowed to swell with CH<sub>2</sub>Cl<sub>2</sub> (3 mL) followed by DMF (3 mL). A solution of 20 % piperidine in DMF (3 × 3 mL) was added to the resin that was then shaken gently on a mechanical shaker for 30 min at ambient temperature. The resin was washed with DMF (3 × 3 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 3 mL). Formation of free amine was assessed by the Kaiser test (Kaiser et al., Anal Biochem, vol. 34, pp. 595-598, 1970). After swelling the resin in DMF, a solution of Fmoc-Phe-OH (3eq), HBTU (3eq), HOBt (3eq), and DIPEA (4.0eq) in DMF was added and gently shaken for 2 h. The resin was then washed with DMF (3 × 3 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 3 mL). The coupling efficiency was assessed by the Kaiser Test. That aforementioned sequence was repeated for two more coupling steps with Fmoc-Phe-OH and DOTA-(t-butyl ester)<sub>3</sub>-CO<sub>2</sub>H. The resulting compound was cleaved from the resin using TFA: CH<sub>2</sub>Cl<sub>2</sub> (1:1) and concentrated under vacuum to produce the free amine. The concentrated product was purified by using a C<sub>18</sub> SepPak Vac 2g column. The product was eluted with a solution 70/30 water/acetonitrile (0.1% TFA in each). ESIMS:827 [M+1]<sup>+</sup>. Lyophilized amine (10 mg, 12 μmol in 2 mL DMF) was added to 1 (prepared separately) (20 mg, 21.4 μmol in 1 mL DMF) followed by TEA (214 μmol, 30 μL) and then stirred at 25°C for 16 h. After solvent removal, solid residue was treated with 3 mL TFA: CH<sub>2</sub>Cl<sub>2</sub> to remove the PMB group. The residue was washed 2 × 5 mL CH<sub>2</sub>Cl<sub>2</sub> to remove impurities. The colorless solid residue thus obtained was purified by a C<sub>18</sub> SepPak Vac 2g column using an eluent of

70/30 water/acetonitrile (0.1% TFA in each) to produce **SRV100** (SR-V-100). The product was further purified using preparative RP-HPLC by Method 1, retention time 17 min. Yield: ~ 30%. ESMS  $m/z$ : 1284[M+H]<sup>+</sup>, HRESI<sup>+</sup>-MS: Calcd. for C<sub>68</sub>H<sub>90</sub>N<sub>11</sub>O<sub>20</sub>, 1284.6365 [M+H], found: 1284.6358. <sup>1</sup>H NMR (CD<sub>3</sub>CO<sub>2</sub>D) δ: 7.35-7.20(m, 10H), 4.86 (bm, 2H), 4.57-4.46 (4H), 4.4-2.8 (m, 14 H), 2.51 (t, 2h), 2.4-1.2 (m, 28H). <sup>13</sup>C (CD<sub>3</sub>CO<sub>2</sub>D) δ: 176.5, 177, 177.06, 177.6, 173.6, 173.24, 161.3, 160.92, 160.53, 160.14, 159.77, 137.95, 137.06, 130.5, 129.5, 127.9, 127.71,, 120.8, 118.0, 115.1, 112.3, 56.1, 55.5, 53.5, 53.3, 40.1, 38.8, 36.832.6, 31.8, 30.7, 29.42, 27.9, 26.53.

**[0186]** 2-[3-(1-Carboxy-5-{7-[5-carboxy-5-(3-phenyl-2-{3-phenyl-2-[2-(4,7,10-tris-carboxymethyl-1,4,7,10tetraaza-cyclododec-1-yl)-acetylamino]-propionylamino}-propionylamino)-pentylcarbamoyl]-heptanoylamino}-pentyl)-ureido]-pentanedioic acid Gallium (III), [<sup>69/71</sup>Ga]SRV100. This compound was prepared according to the same general procedure as described for [<sup>69/71</sup>Ga]SRV27. Compound [<sup>69/71</sup>Ga]SRV100 was purified by Method 1, retention time 22 min. Yield: ~ 30%. ESMS  $m/z$ : 1351 [M+H]<sup>+</sup>, HRESI<sup>+</sup>-MS: Calcd. For C<sub>68</sub>H<sub>86</sub>GaN<sub>11</sub>NaO<sub>20</sub>, 1372.5204 [M+Na]<sup>+</sup>, found: 1372.5199.

#### Compound Characterization - Lipophilicity

**[0187]** Partition coefficients, log<sub>o/w</sub> (pH = 7.4) values were determined according to a literature procedure (Antunes et al., Bioconjug Chem, vol. 18, pp. 84-92, 2007). Briefly, a solution of either [<sup>68</sup>Ga]SRV27 or [<sup>68</sup>Ga]SRV100 was added to a presaturated solution of 1-octanol (5 mL) mixed with phosphate buffered saline (PBS) (5 mL) in a 15 mL centrifuge tube. After vigorously shaking the mixture, it was centrifuged at 3,000 rpm for 5 min. Aliquots (100 μL) were removed from the two phases and the radioactivity was measured in a γ-counter, 1282 Compugamma CS (LKB, Wallac, Turku, Finland).

**[0188]** On analysis of the reaction mixture by HPLC, the retention time of the radiolabeled compound was slightly longer than the corresponding free ligand. The specific radioactivity of purified [<sup>68</sup>Ga]SRV27 and [<sup>68</sup>Ga]SRV100 was between 3.0 and 6.0 MBq/nmol. The log P<sub>octanol/water</sub> values for [<sup>68</sup>Ga]SRV27 and [<sup>68</sup>Ga]SRV100 were approximately -3.9 as determined by the shake-flask method (Antunes et al., Bioconjug Chem, vol. 18, pp. 84-92, 2007). However, using an HPLC method, we found that the HPLC retention times for **SRV100** (28 min) and [<sup>69/71</sup>Ga]SRV100 (32 min) were longer than for **SRV27** (19 min) and [<sup>69/71</sup>Ga]SRV27 (24 min). It is evident that **SRV100** and the corresponding gallium compound were more lipophilic than **SRV27** and its gallium-labeled analog, which is reasonable in light of the presence of two phenylalanine residues in the long linker of **SRV100**, while **SRV27** has only one lysine residue protected as the benzyl ester.

#### Cell Binding Assay

**[0189]** Ki values for **SRV27**, [<sup>69,71</sup>Ga]**SRV27**, **SRV100** and [<sup>69,71</sup>Ga]**SRV100** were determined using a competitive N-acetyl aspartyl glutamate (NAAG) fluorescence cell binding assay adapted from the literature (Kozikowski et al., J Med Chem, vol. 47, pp. 1729-1738, 2004). All compounds were found to be strong inhibitors of PSMA. Compounds **SRV27** and [<sup>69,71</sup>Ga]**SRV27** had inhibitory capacities of 2.9 nM and 29 nM, respectively. For **SRV100** and [<sup>69,71</sup>Ga]**SRV100**, values were 1.23 nM and 0.44 nM, respectively.

### Ex vivo Biodistribution

**[0190]** PSMA+ PC-3 PIP and PSMA- PC-3 flu xenograft-bearing SCID mice were injected via the tail vein with 30 µCi (1.1 MBq) of [<sup>68</sup>Ga]**SRV27** or [<sup>68</sup>Ga]**SRV100**. In case each four mice were sacrificed by cervical dislocation at 30, 60, 120, 180 min p.i. For [<sup>68</sup>Ga]**SRV27** and at 5, 60, 120, 180 min p.i. for [<sup>68</sup>Ga]**SRV100**. The heart, lungs, liver, stomach, pancreas, spleen, fat, kidney, muscle, small and large intestines, urinary bladder, and PC-3 PIP and flu tumors were quickly removed. A 0.1 mL sample of blood was also collected. Each organ was weighed, and the tissue radioactivity was measured with an automated gamma counter (1282 Compugamma CS, Pharmacia/LKB Nuclear, Inc., Gaithersburg, MD). The %ID/g was calculated by comparison with samples of a standard dilution of the initial dose. All measurements were corrected for decay.

**[0191]** Compound [<sup>68</sup>Ga]**SRV27** was assessed for its pharmacokinetics *ex vivo* in severe-combined immunodeficient (SCID) mice bearing both PSMA+ PC3-PIP and PSMA-PC3- flu xenografts (Chang et al., Cancer Res, vol. 59, pp. 3192-3198, 1999). **Table 1** shows the percent injected dose per gram (%ID/g) of radiotracer in selected organs for [<sup>68</sup>Ga]**SRV27**.

**Table 1.** *Ex vivo* tissue biodistribution of [<sup>68</sup>Ga]**SRV27**

Tissue	30 min	60 min	120 min	180 min
blood	2.20 ± 0.90	1.93 ± 0.70	0.80 ± 0.30	0.62 ± 0.34
heart	0.70 ± 0.13	0.50 ± 0.08	0.21 ± 0.08	0.20 ± 0.02
liver	0.84 ± 0.24	0.83 ± 0.10	0.42 ± 0.07	0.50 ± 0.03
stomach	0.73 ± 0.13	0.75 ± 0.32	0.24 ± 0.07	0.24 ± 0.05
spleen	4.90 ± 1.10	3.35 ± 1.20	0.43 ± 0.19	0.32 ± 0.13
kidney	97.19 ± 16.07	64.68 ± 4.10	5.35 ± 2.12	2.13 ± 0.11
muscle	0.46 ± 0.16	0.25 ± 0.07	0.08 ± 0.04	0.05 ± 0.01
small intestine	0.79 ± 0.12	0.70 ± 0.34	0.26 ± 0.11	0.34 ± 0.20
large intestine	0.77 ± 0.14	0.95 ± 0.53	0.34 ± 0.10	0.46 ± 0.10

Tissue	30 min	60 min	120 min	180 min
bladder	8.96 ± 5.30	25.29 ± 8.63	2.70 ± 4.02	5.39 ± 2.98
PC-3 PIP	3.78 ± 0.90	3.32 ± 0.33	1.31 ± 0.06	1.10 ± 0.19
PC-3	flu 0.82 ± 0.20	0.67 ± 0.08	0.41 ± 0.09	0.39 ± 0.02
PIP:flu	4.61	4.93	3.24	2.77
PIP:muscle	8.30	13.13	17.40	20.37
flu:muscle	1.80	2.67	5.37	7.34

[0192] Compound [<sup>68</sup>Ga]SRV27 showed clear PSMA-dependent binding in PSMA+ PC3 PIP xenografts, reaching a maximum uptake of 3.78 ± 0.90 (SEM) %ID/g at 30 min post-injection (p.i.). The blood, spleen and kidney displayed highest uptake at 30 min. By 60 min, the urinary bladder showed highest uptake, however, this uptake represents excretion at all time points. The high values noted in kidney are partially due to high expression of PSMA within proximal renal tubules (Silver et al., Clin Cancer Res, vol. 3, pp. 81-85, 197; Slusher et al., J Comp Neurol, vol. 315, pp. 271-229, 1992). Rapid clearance from the kidneys was demonstrated, decreasing from 97.19 ± 16.07 %ID/g at 30 min to 2.31 ± 0.11%ID/g at 3 h. The radioactivity in the PSMA+ PIP tumor cleared more slowly, from its aforementioned value at 30 min to 1.08 ± 0.19 %ID/g at 3 h.

[0193] Compound [<sup>68</sup>Ga]SRV100 was also investigated for its pharmacokinetic characteristics in tumor bearing mice at 5 min, 1 h, 2 h and 3 h p.i. **Table 2** shows the %ID/g of radiotracer in selected organs for [<sup>68</sup>Ga]SRV100.

**Table 2.** Ex vivo tissue biodistribution of [<sup>68</sup>Ga]SRV100

Tissue	5 min	60 min	120 min	180 min
blood	6.28 ± 0.08 0	.41 ± 0.05	0.15 ± 0.07	0.13 ± 0.01
heart	2.01 ± 0.24	0.19 ± 0.07	0.05 ± 0.03	0.03 ± 0.01
lung	4.59 ± 0.68	0.74 ± 0.54	0.20 ± 0.05	0.14 ± 0.03
liver	1.57 ± 0.16	0.24 ± 0.09	0.19 ± 0.03	0.14 ± 0.02
stomach	2.38 ± 0.35	0.38 ± 0.16	0.18 ± 0.02	0.04 ± 0.02
pancreas	1.52 ± 0.19	0.25 ± 0.14	0.08 ± 0.03	0.04 ± 0.02
spleen	5.17 ± 2.22	2.43 ± 1.07	0.78 ± 0.15	0.34 ± 0.09
fat	1.03 ± 0.02	0.40 ± 0.04	0.08 ± 0.02	0.02 ± 0.01
kidney	64.75 ± 12.00	26.57 ± 10.93	12.25 ± 1.79	10.04 ± 1.22
muscle	1.58 ± 0.33	0.12 ± 0.08	0.03 ± 0.02	0.00 ± 0.01
small intestine	2.04 ± 0.25	0.23 ± 0.05	0.09 ± 0.04	0.06 ± 0.03
large intestine	2.02 ± 0.49	0.50 ± 0.70	0.12 ± 0.03	0.12 ± 0.03
bladder	5.97 ± 1.50	7.65 ± 3.34	1.41 ± 1.17	0.75 ± 0.54

Tissue	5 min	60 min	120 min	180 min
PC-3 PIP	6.61 ± 0.55	2.80 ± 1.32	3.29 ± 0.77	1.80 ± 0.16
PC-3 flu	2.63 ± 0.51	0.16 ± 0.08	0.18 ± 0.03	0.12 ± 0.03
PIP:flu	2.50	17.30	18.28	15.20
Pip:muscle	4.17	23.27	122.13	436.29
flu:muscle	1.67	1.34	6.68	28.70

**[0194]** As for [<sup>68</sup>Ga]SRV27, [<sup>68</sup>Ga]SRV100 showed PSMA-dependent tumor uptake. After a peak, flow-related, uptake at 5 min p.i. of 6.61 ± 0.55%, [<sup>68</sup>Ga]SRV100 demonstrated a 2 h tumor uptake value of 3.29 ± 0.77%, which dropped to 1.80 ± 0.16% at 3 h. Uptake in blood was high at 5 min and rapidly washed out within 1 h. Non-target organs such as kidney, spleen and lung showed high uptake at 5 min and rapidly washed out with time. With the exception of the kidneys and spleen, clearance from blood and normal organs was faster for [<sup>68</sup>Ga]SRV100 than for [<sup>68</sup>Ga]SRV27. Again, high kidney uptake is associated with high expression of PSMA within proximal renal tubules (Silver et al., Clin Cancer Res, vol. 3, pp. 81-85, 1997; Slusher et al., J Comp Neurol, vol. 315, pp. 271-229, 1992). Similar to [<sup>68</sup>Ga]SRV27, [<sup>68</sup>Ga]SRV100 demonstrated faster clearance of radioactivity from kidney than from the PSMA+ tumor. However, the rate of clearance from kidney for [<sup>68</sup>Ga]SRV100 was much slower than for [<sup>68</sup>Ga]SRV27, i.e., 65 ± 12% at 5 min p.i. and 10.04 ± 1.22% at 3 h.

#### **Small Animal PET Imaging**

**[0195]** A single SCID mouse implanted with a PSMA+ LNCaP xenograft was injected intravenously with 0.2 mCi (7.4 MBq) of [<sup>68</sup>Ga]SRV27 in 200 µL 0.9% NaCl. At 0.5 h p.i., the mouse was anesthetized with 3% isoflurane in oxygen for induction and maintained under 1.5% isoflurane in oxygen at a flow rate of 0.8 L/min. The mouse was positioned in the prone position on the gantry of a GE eXplore VISTA small animal PET scanner (GE Healthcare, Milwaukee, WI). Image acquisition was performed using the following protocol: The images were acquired as a pseudodynamic scan, i.e., a sequence of successive whole-body images were acquired in three bed positions for a total of 120 min. The dwell time at each position was 5 min, such that a given bed position (or mouse organ) was revisited every 15 min. An energy window of 250 - 700 keV was used. Images were reconstructed using the FORE/2D-OSEM method (two iterations, 16 subsets) and included correction for radioactive decay, scanner dead time, and scattered radiation. After PET imaging, the mobile mouse holder was placed on the gantry of an X-SPECT (Gamma Medica Ideas, Northridge, CA) small animal imaging device to acquire the corresponding CT. Animals were scanned over a 4.6 cm field-of-view using a 600 µA, 50 kV beam. The PET and CT data were then co-registered using Amira 5.2.0 software (Visage Imaging Inc., Carlsbad, CA).

[0196] Imaging studies of [<sup>68</sup>Ga]SRV100 and blocking studies of [<sup>68</sup>Ga]SRV27 were carried out on PSMA+ PC-3 PIP and PSMA- PC-3 flu xenograft-bearing SCID mice or PSMA+ PC-3 PIP (25.9 MBq in 100 μL NaCl) xenograft-bearing SCID mice. At 30 min, 1 h and 2 h p.i. the mice were anesthetized and whole-body images were obtained using the PET scanner as mentioned above, in two bed positions, 15 min at each position for a total of 30 min using the same energy window. Images were reconstructed and co-registered with the corresponding CT images using the same methods as described above.

[0197] **Figures 2 and 3** demonstrate the high target selectivity of [<sup>68</sup>Ga]SRV27 and [<sup>68</sup>Ga]SRV100 by delineating the PSMA+ tumors. Although a PSMA- control tumor was not included in **Figure 2**, a separate blocking study was performed for [<sup>68</sup>Ga]SRV27, in which an animal pre-treated with 50 mg/kg of the known PSMA-binding ligand, 2-(phosphonomethyl)pentanedioic acid (2-PMPA) (Jackson et al., J Med Chem, vol. 39, pp. 619-622, 1996), did not demonstrate PSMA+ tumor uptake, attesting to the binding specificity of this compound. The more quantitative, *ex vivo* studies of [<sup>68</sup>Ga]SRV27 and [<sup>68</sup>Ga]SRV100 further supported high PSMA target specificity, demonstrating target-to-nontarget (PIP/flu) ratios of approximately 5 and 18 at 1 h and 2 h p.i., respectively. One hour and 2 h PSMA+ tumor uptake values for these compounds,  $3.32 \pm 0.33\%$  and  $3.29 \pm 0.77\%$ , respectively, for [<sup>68</sup>Ga]SRV27 and [<sup>68</sup>Ga]SRV100, are comparable to other radiometallated PSMA inhibitors (Banerjee et al., J Med Chem, vol. 51, pp. 4504-4517, 2008). As shown in **Figures 2 and 3** those values are sufficient for clear tumor imaging. Notably, PIP tumors contain about one order of magnitude lower PSMA than LNCaP tumors (data not shown), which are often employed to assess for binding specificity of PSMA-targeting agents. PIP/flu is the preferred comparison as both are derived from PC-3 cells, providing a more controlled study.

[0198] Intense radiotracer uptake was seen only in the kidneys and tumor for both [<sup>68</sup>Ga]SRV27 (**Figure 2**) and [<sup>68</sup>Ga]SRV100 (**Figure 3**). As noted above for the *ex vivo* study, the intense renal uptake was partially due to specific binding of the radiotracer to proximal renal tubules (Silver et al., Clin Cancer Res, vol. 3, pp. 81-85, 1997; Slusher et al., J Comp Neurol, vol. 315, pp. 271-229, 1992) as well as to excretion of this hydrophilic compound. Apart from the kidneys, only the PSMA+ tumor demonstrated significant radiotracer uptake.

## **Discussion**

[0199] Because of its demonstrated clinical utility and the appearance of dual modality (PET/computed tomography (CT)) systems, clinical PET imaging has been accelerating worldwide and may soon become the dominant technique in nuclear medicine. PET isotopes tend to be short-lived and enable synthesis of "physiologic" radiotracers, namely, those that incorporate <sup>15</sup>O, <sup>13</sup>N or <sup>11</sup>C, enabling precise conformity to the tracer principle. Being essentially isosteric to H, <sup>18</sup>F enables nearly tracer-level studies, with important caveats,


particularly for [ $^{18}\text{F}$ ]fluorodeoxyglucose (FDG), which is by far the most commonly used radiopharmaceutical for PET. But, in part because FDG does not accumulate well within many tumor types, including prostate cancer, there has been a re-emergence in the development of radiometallated peptides, often employing  $^{99\text{m}}\text{Tc}$ , that target G-protein coupled receptors. Gallium-68 provides a link between PET and single photon emission computed tomography (SPECT) since metal chelating methodology needed for  $^{99\text{m}}\text{Tc}$  can also be applied to  $^{68}\text{Ga}$ . A further analogy is the convenience of use of a  $^{68}\text{Ge}/^{68}\text{Ga}$  generator (PET), as with  $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$  (SPECT), to provide readily available isotope, with no need for an in-house cyclotron. Although  $^{18}\text{F}$ -labeled, low molecular weight PSMA inhibitors have shown promise in preclinical imaging studies (Mease et al., Clin Cancer Res, vol. 14, pp. 3036-3043, 2008; Lapi et al., J Nucl Med, vol. 50, pp. 2042-2048, 2009), the availability of generator-produced  $^{68}\text{Ga}$  and the extension to PET from our published  $^{99\text{m}}\text{Tc}$ -labeled series of PSMA-binding radiometallated imaging agents (Banerjee et al., J Med Chem, vol. 51, pp. 4504-4517, 2008) provided the rationale for this study.


### EXAMPLE 3

**[0200]** Compound **SRV27** and **SRV100** were prepared as described in Example 2. In-111 labeling was generally performed by treatment of SRV27 or SRV100 or SRV73 with  $^{111}\text{InCl}_3$ , in 200 mM aqueous NaOAc  $\sim 60^\circ\text{C}$  for 30 minutes. Specifically, for SRV27, 60  $\mu\text{l}$  of SRV27 (2 mg/mL, sodium acetate) was combined with 100  $\mu\text{l}$  sodium acetate and 3mCi  $^{111}\text{InCl}_3$  in a 1.5 ml appendorf tube and left at for  $60^\circ\text{C}$  for 30 min. The radiolabeled product was diluted with 800  $\mu\text{l}$  water and purified by HPLC. Radiolabeling yield is 1.7 mCi (-57%) and radiochemical purity was  $> 99.9\%$

### SRV73 (not according to the invention)

**[0201]** Compound SRV73 was prepared by the method outlined in the scheme below. Compound SRV73 is a bimodal compound having a fluorescent dye moiety and a metal chelating moiety





### **Small animal PET imaging**

**[0202]** SPECT imaging experiments for [<sup>111</sup>In]SRV27, [<sup>111</sup>In]SRV100 and [<sup>111</sup>In]SRV73 were performed using the same general procedure described for [<sup>99m</sup>Tc]SRV32 described in Example 1.

**[0203]** SPECT-CT imaging experiment of compound [<sup>111</sup>In]SRV27 (**Figure 5**) illustrated clear PSMA-dependent binding in PSMA+ PC3 PIP xenografts within 1 h post injection. The high values noted in kidney are partially due to high expression of PSMA within proximal renal tubules (Silver et al., Clin Cancer Res, vol. 3, pp. 81-85, 197; Slusher et al., J Comp Neurol, vol. 315, pp. 271-229, 1992). Rapid clearance from the kidneys was observed while the activity retained in PSMA+ tumor even after four days post injection.


**[0204]** SPECT-CT imaging experiment of compound [<sup>111</sup>In]SRV100 (**Figure 6**) demonstrated similar clear PSMA-dependent binding in PSMA+ PC3 PIP xenografts within 2 h post injection. The high values noted in kidney are partially due to high expression of PSMA within proximal renal tubules (Silver et al., Clin Cancer Res, vol. 3, pp. 81-85, 197; Slusher et al., J Comp Neurol, vol. 315, pp. 271-229, 1992). Rapid clearance from the kidneys was observed while the activity retained in PSMA+ tumor even after four days post injection. The longer tumor activity retention for [<sup>111</sup>In]SRV27 and [<sup>111</sup>In]SRV100 might be useful Y-90/Lu-177 based radiotherapeutic application.


**[0205]** **Figure 7** demonstrates clear tumor uptake for [<sup>111</sup>In]SRV73 at 7 h post injection. This is significant since after attaching a bulky fluorescent dye, rhodamine, the compound retains its PSMA binding activity. This is an example of dual modality application for this class of compounds.

### **EXAMPLE 4**

**SRVI34**

[0206] **2-{3-[1-Carboxy-5-(7-{5-carboxy-5-[3-phenyl-2-(3-phenyl-2-{2-[2-(2-tritylsulfanyl-acetylamino)-acetylamino]-acetylamino]-propionylamino)-propionylamino]-pentylcarbamoyl]-heptanoylamino)-pentyl]-ureido}-pentanedioic acid (SRVI34)**. SRVI34 was prepared according to the scheme below. Lys(Boc)-Wang resin (100 mg, 0.43 mM) was allowed to swell with CH<sub>2</sub>Cl<sub>2</sub> (3 mL) followed by DMF (3 mL). A solution of 20% piperidine in DMF (3 × 3 mL) was added to the resin that was then shaken gently on a mechanical shaker for 30 min at ambient temperature. The resin was washed with DMF (3 × 3 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 3 mL). Formation of free amine was assessed by the Kaiser test. After swelling the resin in DMF, a solution of Fmoc-Phe-OH (3 eq), HBTU (3eq), HOBt (3 eq), and DIPEA (4.0 eq) in DMF was added and gently shaken for 2 h. The resin was then washed with DMF (3 × 3 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 3 mL). The coupling efficiency was assessed by the Kaiser Test. That aforementioned sequence was repeated for four more coupling steps with Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Gly-OH and S-trityl mercaptoacetic acid. Finally the product was cleaved from the resin using TFA:CH<sub>2</sub>Cl<sub>2</sub> (1:1) and concentrated under vacuum to produce the free amine (SRVI32). The concentrated product was purified by using a C<sub>18</sub> SepPak Vac 2g column. The product was eluted with a solution 70/30 water/acetonitrile (0.1% TFA in each). ESIMS: [M+1]<sup>+</sup>. Lyophilized SRVI32 (10 mg, 12 μmol in 2 mL DMF) was added to the urea (compound 1 described in Example 2) (20 mg, 21.4 μmol in 1 mL DMF) followed by TEA (214 μmol, 30 μL) and then stirred at 25°C for 16 h. The residue was washed 2 × 5 mL CH<sub>2</sub>Cl<sub>2</sub> to remove impurities. The colorless solid residue thus obtained was purified by a C<sub>18</sub> SepPak Vac 2g column using an eluent of 70/30 water/acetonitrile (0.1% TFA in each). The product was further purified using preparative RP-HPLC by Method 1, retention time 17 min. Yield: ~ 30%. ESMS m/Z: 1328 [M+H]<sup>+</sup>, <sup>1</sup>H NMR (D<sub>2</sub>O/CD<sub>3</sub>CN (1:1)) δ: 7.98 (m, 5H), 7.90-7.76 (m, 18H), 7.66 (m, 2H), 5.11 (m, 1H), 4.82-4.72 (m, 3H), 4.28 (m, 2H), 4.16 (m, 2H), 3.68 (m, 5H), 3.49-3.32 (m, 2H), 3.00 (m, 2H), 2.69 (m, 4H), 2.64-1.74 (m, 26H).





a. (i) 20% piperidine/DMF; (ii) Fmoc-Phe-OH, HOBT, HBTU, DIEA; (iii) 20% piperidine/DMF; (iv) Fmoc-Phe-OH, HOBT, HBTU, DIEA; (v) 20% piperidine/DMF; (vi) Fmoc-Gly-OH, HOBT, HBTU, DIEA; (vii) 20% piperidine/DMF; (viii) Fmoc-Gly-OH, HOBT, HBTU, DIEA; (ix) 20% piperidine/DMF; (x) (S-Ph<sub>3</sub>)-CH<sub>2</sub>CO<sub>2</sub>H, HOBT, HBTU, DIEA; (xi) TFA/CH<sub>2</sub>Cl<sub>2</sub>; b. TEA, DMF; c. TcO<sub>4</sub><sup>-</sup>, SnCl<sub>2</sub>, sodium ascorbate, Na-tartrate, NH<sub>4</sub>OAc, pH 7.5.

**[0207] Radiolabeling with Tc-99m:** Radiolabeling was performed following a literature procedure (Wang et al., Nature Protocols, vol. 1, pp. 1477-1480, 2006). Briefly, 1 mg (75.3 μmol) of compound SRVI34 was dissolved in 1 ml of 0.5 M ammonium acetate buffer at pH 8. Disodium tartarate dihydrate was dissolved in the labelling buffer of 0.5 M ammonium acetate (pH 8) to a concentration of 50 mg/ml. Ascorbic acid-HCl solution was prepared by dissolving ascorbic acid in 10 mM HCl to a concentration of 1.0 mg/ml. A solution of SRVI34 (80 μl) was combined to a solution of 45 μl 0.25 M ammonium acetate, 15 μl tartarate buffer, followed by 5 μl of the freshly prepared 4 mg/ml SnCl<sub>2</sub> · 2H<sub>2</sub>O solution in the ascorbate-HCl solution. The final pH will be about 8-8.5. After vortexing, was added 20 mCi of <sup>99m</sup>Tc-pertechnetate in 200 μl saline and was heated the solution at 90-100°C for 20 min. Reaction mixture was cooled, diluted 850 μl of water and purified by HPLC using a Phenomenex C<sub>18</sub> Luna 10 × 250 mm<sup>2</sup> column on a Waters 600E Delta LC system with a Waters 486 tunable absorbance UV/Vis detector, both controlled by Empower software. HPLC solvent system, flow rate= 4 ml/min, a gradient, 0-5 min, 80/20 water/acetonitrile (0.1% TFA in each solvent), 5-25 min 40/60 water/acetonitrile (0.1% TFA in each solvent) and 25-35 min 80/20 (0.1% TFA in each solvent) was used. Two radiolabeled products were found, called as [<sup>99m</sup>Tc]SRVI34A (5.52 mCi) (retention time 17.5 min) and [<sup>99m</sup>Tc]SRVI34B (6 mCi) (retention time 18.9 min). SRVI34A and SRVI32B are diastereomers, syn and anti-isomers with respect to the Tc=O group. Each product was neutralized with 50 μl of 1 M sodium bicarbonate and evaporated to dryness under vacuum. The obtained solid residues was dissolved in 200 μl saline and used for imaging and biodistribution studies.

### **Ex vivo Biodistribution**

**[0208]** PSMA+ PC-3 PIP and PSMA- PC-3 flu xenograft-bearing SCID mice were injected via the tail vein with 30 μCi [<sup>99m</sup>Tc]SRVI34B. Four mice were sacrificed by cervical dislocation at

30, 60, 120, and 300 min p.i. The heart, lungs, liver, stomach, pancreas, spleen, fat, kidney, muscle, small and large intestines, urinary bladder, and PC-3 PIP and flu tumors were quickly removed. A 0.1 mL sample of blood was also collected. Each organ was weighed, and the tissue radioactivity was measured with an automated gamma counter (1282 Compugamma CS, Pharmacia/LKB Nuclear, Inc., Gaithersburg, MD). The %ID/g was calculated by comparison with samples of a standard dilution of the initial dose. All measurements were corrected for decay.

**[0209]** Compound [ $^{99m}\text{Tc}$ ]SRVI34B was assessed for its pharmacokinetics *ex vivo* in severe-combined immunodeficient (SCID) mice bearing both PSMA+ PC3-PIP and PSMA-PC3- flu xenografts (Chang et al., Cancer Res, vol. 59, pp. 3192-3198, 1999). **Table 3** shows the percent injected dose per gram (%ID/g) of radiotracer in selected organs for [ $^{99m}\text{Tc}$ ]SRVI34B.

Table 3: Biodistribution data for [ $^{99m}\text{Tc}$ ]SRVI34B (n = 4)

	30 min	60 min	120 min	300 min
Blood	1.13±1.06	0.69±0.08	0.27±0.09	0.23±0.00
heart	1.11±0.06	0.70±0.16	0.61±0.07	0.46±0.05
lung	4.08±0.31	4.84±1.26	4.02±0.73	2.79±0.74
liver	1.55±0.23	0.92±0.37	0.50±0.085	0.24±0.09
stomach	0.79±0.23	0.77±0.17	0.54±12	0.27±0.08
pancreas	1.72±0.74	1.42±0.45	1.02±0.29	0.94±0.46
spleen	56.44±16.49	64.24±13.29	58.27±18.26	24.49±3.63
fat	2.18037±0.50	2.13±0.58	1.82±0.37	0.99±0.03
kidney	62.45±1.63	96.38±22.74	104.84±19.03	116.14±2.71
muscle	1.20±0.12	0.74±0.04	1.29±1.31	0.45±0.31
small intestine	1.03±0.40	1.43±0.66	0.79±0.33	0.23±0.12
large intestine	0.61±0.03	0.63±0.38	0.35±0.12	1.30±0.08
bladder	1.28±0.25	2.07±0.96	0.87±0.33	0.51±0.00
PC-3 PIP	6.11±0.94	7.99±2.26	6.96±1.13	4.81±0.66
PC-3 flu	0.98±0.38	0.76±0.51	0.50±0.28	0.22±0.11
PIP:flu	6.28	10.56	14.05	22.18

### **Small Animal SPECT-CT Imaging**

**[0210]** Imaging experiments for [ $^{99m}\text{Tc}$ ]SRVI34A and [ $^{99m}\text{Tc}$ ]SRVI34B were done following the same procedures as was done for [ $^{99m}\text{Tc}$ ]SRV32 (Example 1).

[0211] Figures 13, 14, 15, and 16 demonstrate the high target selectivity of [ $^{99m}\text{Tc}$ ]SRVI34B by delineating the PSMA+ tumors. The compound [ $^{99m}\text{Tc}$ ]SRVI34B exhibited high uptake in PSMA+ tumor and no uptake in PSMA- tumor. The tumor uptake remains high 4.88% ID/g even at 5 hr post inject (p.i.). However this compound showed very high kidney uptake 116% ID/g even at 5 hr p.i. In addition this compound showed high spleen uptake 24.5 %ID/g at 5 hr p.i.


## EXAMPLE 5

### General

[0212] All reagents and solvents were purchased from either Sigma-Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA). 2-{3-[5-[7-(2,5-Dioxo-pyrrolidin-1-yl)oxycarbonyl]-heptanoylamino]-1-(4-methoxy-benzyloxycarbonyl)-pentyl]-ureido}-pentanedioic acid bis-(4-methoxy-benzyl) ester (**1**) was prepared according to (Banerjee et al., J. Med. Chem., vol. 51, pp. 4504-4517, 2008). H-Lys(Boc)-OBu·HCl was purchased from Chem-Impex International (Wood Dale, IL). The N-hydroxysuccinimide (NHS) ester of IRDye 800CW was purchased from LI-COR Biosciences (Lincoln, NE).  $^1\text{H}$  NMR spectra were obtained on a Bruker Avance 400 MHz Spectrometer. ESI mass spectra were obtained on a Bruker Esquire 3000 plus system. Purification by high-performance liquid chromatography (HPLC) was performed on a Varian Prostar System (Varian Medical Systems, Palo Alto, CA).

### YC-27 (not according to the invention)

[0213] Compound YC-27 was prepared according the scheme shown below.




(a) H-Lys(Boc)-OBU·HCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (b) TFA:CH<sub>2</sub>Cl<sub>2</sub> = 1:1; (c) IRDye800CW-NHS, DIPEA, DMSO

**[0214] Trifluoroacetate salt of 2-(3-{5-[7-(5-amino-1-carboxy-pentylcarbamoyl)-heptanoylamino]-1-carboxy-pentyl}-ureido)-pentanedioic acid (YC-VIII-24).** (not according to the invention) To a solution of 1 (0.065 g, 0.020 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added triethylamine (0.040 mL, 0.285 mmol), followed by H-Lys(Boc)-OBU·HCl (0.028 g, 0.083 mmol). After stirring for 2 h at room temperature, the solvent was evaporated on a rotary evaporator. A solution of TFA/CH<sub>2</sub>Cl<sub>2</sub> 1:1 (2 mL) was then added to the residue and stirred for 1 h at room temperature. The crude material was purified by HPLC (column, Econosphere C18, 10μ, 250 × 10 mm; retention time, 15 min; mobile phase, A = 0.1% TFA in H<sub>2</sub>O, B = 0.1% TFA in CH<sub>3</sub>CN; gradient, 0 min = 5% B, 25 min = 25% B; flow rate, 4 mL/min) to afford 0.032 g (66%) of **YC-VIII-24**. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 4.24-4.28 (m, 1H), 4.17-4.20 (m, 1H), 4.08-4.12 (m, 1H), 3.08-3.12 (m, 2H), 2.88-2.92 (m, 2H), 2.41-2.44 (m, 2H), 2.19-2.21 (m, 2H), 2.05-2.16 (m, 3H), 1.57-1.93 (m, 7H), 1.21-1.50 (m, 10H), 1.21 (m, 4H). ESI-Mass calcd for C<sub>26</sub>H<sub>46</sub>N<sub>5</sub>O<sub>11</sub> [M]<sup>+</sup> 604.3, found 604.0.

**[0215] YC-27.** (not according to the invention) To a solution of **YC-VIII-24** (0.3 mg, 0.43 μmol) in DMSO (0.1 mL) was added N, N-diisopropylethylamine (0.002 mL, 11.4 μmol), followed by the NHS ester of IRDye 800CW (0.3 mg, 0.26 μmol). After stirring for **YC-VIII-24** for 2 h at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5μ, 150 × 4.6 mm; retention time, 22 min, mobile phase, A = 0.1% TFA in H<sub>2</sub>O, B = 0.1% TFA in CH<sub>3</sub>CN; gradient, 0 min = 0% B, 5 min = 0% B, 45 min = 100% B; flow rate, 1 mL/min) to afford 0.3 mg (72%) of **YC-27**. ESI-Mass calcd for C<sub>72</sub>H<sub>97</sub>N<sub>7</sub>O<sub>25</sub>S<sub>4</sub> [M]<sup>+</sup> 1587.5, found 794.3 [M+H]<sup>2+</sup>, 1587.6 [M]<sup>+</sup>.

### Synthesis of precursor YC-VI-54


**[0216]**



**[0217]** To a solution of Lys-Urea-Glu (0.103 g, 0.121 mmol, Banerjee et al J. Med. Chem., vol. 51, pp. 4507-4517, 2008) in DMF (2 mL) was added Boc-NH-PEG-COOH (0.060 g, 0.135 mmol) and TBTU (0.040g, 0.125 mmol), followed by *N,N*-diisopropylethylamine (0.042 mL, 0.241 mmol). After stirring overnight at room temperature, the solvent was evaporated on a rotary evaporator. The crude material was purified by a silica column using methanol/methylene chloride (5:95) to afford 0.101 g (0.109 mmol, 90%) of YC-VI-53, which was dissolved in a solution of 3% anisole in TFA (1 mL). The mixture was reacted at room temperature for 10 min, then concentrated on a rotary evaporator. The crude material was purified by HPLC (Econosphere C18 10u, 250 × 10 mm, H<sub>2</sub>O/CH<sub>3</sub>CN/TFA (92/8/0.1), 4 mL/min, Compound **YC-VI-54** eluting at 11 min) to afford 0.035 g (57%) of compound **YC-VI-54**. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 4.17-4.21 (m, 1H), 4.10-4.13 (m, 1H), 4.00 (s, 2H), 3.67-3.71 (m, 6H), 3.14-3.20 (m, 4H), 2.43-2.46 (m, 2H), 2.08-2.13 (m, 1H), 1.87-1.93 (m, 1H), 1.76-1.79 (m, 1H), 1.63-1.67 (m, 1H), 1.45-1.50 (m, 2H), 1.33-1.40 (m, 2H). ESI-Mass calcd for C<sub>18</sub>H<sub>33</sub>N<sub>4</sub>O<sub>10</sub> [M]<sup>+</sup> 465.2, found 465.2.

**YC-VIII-11** (not according to the invention)


**[0218]**



**[0219]** To a solution of compound **YC-VI-54** (0.3 mg, 53 μmol) in DMSO (0.05 mL) was added *N,N*-diisopropylethylamine (0.002 mL, 11.4 μmol), followed by NHS ester of IRDye 800RS (0.2 mg, 0.21 μmol). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5μ, 150 × 4.6 mm; retention time, 28 min; mobile phase, A = 0.1% TFA in H<sub>2</sub>O, B = 0.1% TFA in CH<sub>3</sub>CN; gradient, 0 mins = 0% B, 5 mins = 0% B, 45 mins = 100% B; flow rate, 1 mL/min) to afford 0.2 mg (75%) of compound **YC-VIII-11**. ESI-Mass calcd for C<sub>64</sub>H<sub>84</sub>N<sub>6</sub>O<sub>18</sub>S<sub>2</sub> [M]<sup>+</sup> 1288.5, found 1288.9.

**YC-VIII-12** (not according to the invention)


[0220]



[0221] To a solution of compound **YC-VI-54** (0.3 mg, 53  $\mu\text{mol}$ ) in DMSO (0.05 mL) was added *N,N*-diisopropylethylamine (0.002 mL, 11.4  $\mu\text{mol}$ ), followed by NHS ester of IRDye800CW (0.2 mg, 0.17  $\mu\text{mol}$ ). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5 $\mu$ , 150  $\times$  4.6 mm; retention time, 22 min; mobile phase, A = 0.1% TFA in H<sub>2</sub>O, B = 0.1% TFA in CH<sub>3</sub>CN; gradient, 0 mins = 0% B, 5 mins = 0% B, 45 mins = 100% B; flow rate, 1 mL/min) to afford 0.2 mg (80%) of compound **YC-VIII-12**. ESI-Mass calcd for C<sub>64</sub>H<sub>84</sub>N<sub>6</sub>O<sub>24</sub>S<sub>4</sub> [M]<sup>+</sup> 1448.4, found 1448.7.

**YC-VIII-28** (not according to the invention)

[0222]




[0223] To a solution of **YC-VIII-24** (prepared as described previously for YC-27) (0.3 mg, 0.42  $\mu\text{mol}$ ) in DMSO (0.1 mL) was added *N,N*-diisopropylethylamine (0.002 mL, 11.5  $\mu\text{mol}$ ), followed by NHS ester of IRDye 800RS (0.3 mg, 0.31  $\mu\text{mol}$ ). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5 $\mu$ , 150  $\times$  4.6 mm; retention time, 27 min; mobile phase, A = 0.1% TFA in H<sub>2</sub>O, B = 0.1% TFA in CH<sub>3</sub>CN; gradient, 0 mins =

0% B, 5 mins = 0% B, 45 mins = 100% B; flow rate, 1 mL/min) to afford 0.3 mg (67%) of compound **YC-VIII-28**. ESI-Mass calcd for  $C_{72}H_{97}N_7O_{19}S_2$   $[M]^+$  1427.6, found 714.4  $[M+H]^{2+}$ , 1427.8  $[M]^+$ .

**YC-VIII-30 (not according to the invention)**


[0224]



[0225] To a solution of **YC-VIII-24** (0.5 mg, 0.70  $\mu\text{mol}$ ) in DMSO (0.1 mL) was added *N,N*-diisopropylethylamine (0.005 mL, 28.7  $\mu\text{mol}$ ), followed by NHS ester of BODIPY 650/665-X (0.3 mg, 0.47  $\mu\text{mol}$ ). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5 $\mu$ , 150  $\times$  4.6 mm; retention time, 28 min; mobile phase, A = 0.1% TFA in  $H_2O$ , B = 0.1% TFA in  $CH_3CN$ ; gradient, 0 mins = 0% B, 5 mins = 0% B, 45 mins = 100% B; flow rate, 1 mL/min) to afford 0.4 mg (75%) of compound **YC-VIII-30**. ESI-Mass calcd for  $C_{55}H_{73}BF_2N_9O_{14}$   $[M+H]^+$  1132.5, found 1132.0.

**YC-VIII-31 (not according to the invention)**

[0226]




[0227] To a solution of **YC-VI-54** (0.5 mg, 0.70  $\mu\text{mol}$ ) in DMSO (0.1 mL) was added *N,N*-diisopropylethylamine (0.005 mL, 28.7  $\mu\text{mol}$ ), followed by NHS ester of BODIPY 650/665-X (0.3 mg, 0.47  $\mu\text{mol}$ ). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5 $\mu$ , 150  $\times$  4.6 mm; retention time, 29 min; mobile phase, A = 0.1% TFA in  $H_2O$ , B = 0.1% TFA in  $CH_3CN$ ; gradient, 0 mins = 0% B, 5 mins = 0% B, 45 mins = 100% B; flow rate, 1 mL/min) to afford 0.4 mg (86%) of compound **YC-VIII-31**. ESI-Mass calcd for

$C_{47}H_{59}BF_2N_8O_{13}$   $[M]^+$  992.4, found 992.9.

**YC-VIII-41 (not according to the invention)**


[0228]



[0229] To a solution of Lys-Urea-Glu (4.0 mg, 9.6  $\mu$ mol) in DMF (0.5 mL) was added triethylamine (0.01 mL, 71.7  $\mu$ mol), followed by Marina Blue-NHS ester (1.8 mg, 4.9  $\mu$ mol). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 10 $\mu$ , 250  $\times$  10 mm; retention time, 14 min; mobile phase, H<sub>2</sub>O/CH<sub>3</sub>CN/TFA = 85/15/0.1; flow rate, 4 mL/min) to afford 2.5 mg (89%) of compound **YC-VIII-41**. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O)  $\delta$  7.40 (d, J = 11.6 Hz, 1H), 4.23-4.31 (m, 1H), 4.15-4.19 (m, 1H), 3.64 (s, 2H), 3.19-3.23 (m, 2H), 2.49-2.53 (m, 2H), 2.39 (s, 3H), 2.06-2.17 (m, 1H), 1.95-1.99 (m, 1H), 1.83-1.90 (m, 1H), 1.72-1.80 (m, 1H), 1.52-1.55 (m, 2H), 1.40-1.45 (m, 2H). ESI-Mass calcd for  $C_{24}H_{28}F_2N_3O_{11}$   $[M+H]^+$  572.2, found 571.8.

**YC-VIII-52 (not according to the invention)**

[0230]




[0231] To a solution of Lys-Urea-Glu (4.0 mg, 9.6  $\mu$ mol) in DMSO (0.5 mL) was added N,N-diisopropylethylamine (0.020 mL, 114.8  $\mu$ mol), followed by 4-[2-(4-dimethylamino-phenyl)-vinyl]-1-(3-isothiocyanato-propyl)-pyridium (3 mg, 7.4  $\mu$ mol). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 10 $\mu$ , 250  $\times$  10 mm;

retention time, 13 min; mobile phase, A = 0.1% TFA in H<sub>2</sub>O, B = 0.1% TFA in CH<sub>3</sub>CN; gradient, 0 mins = 10% B, 20 mins = 60% B; flow rate, 4 mL/min) to afford 1.3 mg (24%) of compound **YC-VIII-52**. ESI-Mass calcd for C<sub>31</sub>H<sub>43</sub>N<sub>6</sub>O<sub>7</sub>S [M]<sup>+</sup> 643.3, found 642.9.

**YC-VIII-74 (not according to the invention)**


[0232]



[0233] To a solution of **YC-VIII-24** (3.0 mg, 4.2 μmol) in DMSO (0.5 mL) was added *N,N*-diisopropylethylamine (0.020 mL, 114.8 μmol), followed by 4-[2-(4-dimethylaminophenyl)-vinyl]-1-(3-isothiocyanato-propyl)-pyridium (2 mg, 4.9 μmol). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5μ, 150 × 4.6 mm; retention time, 15 min; mobile phase, A = 0.1% TFA in H<sub>2</sub>O, B = 0.1% TFA in CH<sub>3</sub>CN; gradient, 0 mins = 0% B, 5 mins = 0% B, 45 mins = 100% B; flow rate, 1 mL/min) to afford 2 mg (47%) of compound **YC-VIII-74**. ESI-Mass calcd for C<sub>45</sub>H<sub>67</sub>N<sub>8</sub>O<sub>11</sub>S [M]<sup>+</sup> 927.5, found 927.0.

**YC-VIII-63 (not according to the invention)**

[0234]




[0235] To a solution of **YC-VIII-24** (5.0 mg, 7.0 μmol) in DMF (1 mL) was added triethylamine (0.020 mL, 143.5 μmol), followed by NHS ester of 5-(and-6)-carboxynaphthofluorescein (4.0 mg, 7.0 μmol). After 1 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 10μ, 250 × 10 mm; retention time, minor product at 17 min, major

product at 20 min); mobile phase, H<sub>2</sub>O/CH<sub>3</sub>CN/TFA = 70/30/0.1; flow rate, 4 mL/min) to afford 0.3 mg of minor and 2.2 mg of major product (two isomers of **YC-VIII-63**). ESI-Mass calcd for C<sub>55</sub>H<sub>59</sub>N<sub>5</sub>O<sub>17</sub> [M]<sup>+</sup> 1061.4, found 1061.6 (for both minor and major product).

### **YC-IX-92 (not according to the invention)**

[0236]



[0237] To a solution of Lys-Urea-Glu (0.2 mg, 0.48 μmol) in DMSO (0.05 mL) was added A,A-diisopropylethylamine (0.002 mL, 11.5 μmol), followed by NHS ester of IRDye 800RS (0.2 mg, 0.21 μmol). After 2 hour at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5μ, 150 × 4.6 mm; retention time, 23 min; mobile phase, A = 0.1% TFA in H<sub>2</sub>O, B = 0.1% TFA in CH<sub>3</sub>CN; gradient, 0 mins = 0% B, 5 mins = 0% B, 45 mins = 100% B; flow rate, 1 mL/min) to afford 0.2 mg (84%) of compound **YC-IX-92**. ESI-Mass calcd for C<sub>58</sub>H<sub>73</sub>N<sub>5</sub>O<sub>15</sub>S<sub>2</sub> [M]<sup>+</sup> 1143.5, found 572.5 [M+H]<sup>2+</sup>, 1144.0 [M]<sup>+</sup>.

### **Characterization - Fluorescence**

[0238] Fluorescence spectra were recorded using a Varian Cary Eclipse fluorescence spectrophotometer (Varian Medical Systems) with excitation from a Xenon arc lamp. **YC-27** was dissolved in water. All of the fluorescence measurements were performed in aqueous solution under ambient conditions. The fluorescence quantum yield of **YC-27** was measured using an aqueous solution of ICG ( $\Phi = 0.016$  (Sevick-Muraca et al., Photochem. Photobiol., vol. 66, pp. 55-64, 1997), excitation wavelength at 775 nm) as the standard (**Figure 8**). The fluorescence intensity data were collected in the spectral region 780 - 900 nm over which quantum yield was integrated. Time-resolved intensity decays were recorded using a PicoQuant Fluotime 100 time-correlated single-photon counting (TCSPC) fluorescence lifetime spectrometer (PicoQuant, Berlin, DE). The excitation was obtained using a pulsed laser diode (PicoQuant PDL800-B) with a 20 MHz repetition rate. The fluorescence intensity decay of **YC-27** was analyzed in terms of the single-exponential decay using the PicoQuant Fluofit 4.1 software with deconvolution of the instrument response function and nonlinear least squares fitting. The goodness-of-fit was determined by the  $\chi^2$  value.

[0239] The electronic spectrum of **YC-27** exhibited an absorbance maximum at 774 nm with an extinction coefficient of  $158,900 \text{ M}^{-1}$ . Upon excitation, **YC-27** provided intense fluorescence with an emission maximum at 792 nm and a fluorescence lifetime of 443 psec in aqueous solution (**Figure 9**). Using an excitation wavelength of 775 nm, **YC-27** demonstrated a fluorescence quantum yield of 0.053 in aqueous solution relative to ICG, which demonstrated a quantum yield of 0.016 (**Figure 8**) (Sevick-Muraca et al., Photochem. Photobiol., vol. 66, pp. 55-64, 1997), attesting to the efficiency of this IRDye 800CW-based compound. That is significant because ICG has been used previously for intraoperative tumor mapping (K. Gotoh, T. Yamada, O. Ishikawa, H. Takahashi, H. Eguchi, M. Yano, H. Ohigashi, Y. Tomita, Y. Miyamoto, and S. Imaoka, A novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation. J. Surg. Oncol., 2009).

### **In vitro NAALADase Activity**

[0240] PSMA inhibitory activity of **YC-27** was determined using a fluorescence-based assay according to a previously reported procedure (Chen et al., J. Med. Chem., vol. 51, pp. 7933-7943, 2008). Briefly, lysates of LNCaP cell extracts (25  $\mu\text{L}$ ) were incubated with the inhibitor (12.5  $\mu\text{L}$ ) in the presence of 4  $\mu\text{M}$  *N*-acetyl aspartyl glutamate (NAAG) (12.5  $\mu\text{L}$ ) for 120 min. The amount of glutamate released by NAAG hydrolysis was measured by incubation with a working solution (50  $\mu\text{L}$ ) of the Amplex Red Glutamic Acid Kit (Molecular Probes Inc., Eugene, OR) for 60 min. Fluorescence was measured with a VICTOR<sup>3</sup>V multilabel plate reader (Perkin Elmer Inc., Waltham, MA) with excitation at 530 nm and emission at 560 nm. Inhibition curves were determined using semi-log plots, and  $\text{IC}_{50}$  values were determined at the concentration at which enzyme activity was inhibited by 50%. Assays were performed in triplicate. Enzyme inhibitory constants ( $K_i$  values) were generated using the Cheng-Prusoff conversion [19]. Data analysis was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, California).

[0241] This assay is free from the interference of IRDye 800CW because the excitation/emission maxima of IRDye 800CW are remote from those of resorufin ( $\lambda_{\text{ex}} = 563 \text{ nm}$ ,  $\lambda_{\text{em}} = 587 \text{ nm}$ ), which provides the fluorescent readout in the assay. The  $K_i$  value of **YC-27** was 0.37 nM with 95% confidence intervals from 0.18 nM to 0.79 nM. Under the same experimental conditions, the  $K_i$  value of the known PSMA inhibitor ZJ-43 (Zhou et al., Nat. Rev. Drug Discov., vol. 4, pp. 1015-1026, 2005) was 2.1 nM, indicating the high inhibitory capacity of **YC-27**. The inhibition curve of **YC-27**, which is expressed with respect to the amount of glutamate released from hydrolysis of NAAG, is shown in **Figure 10**.

### **Biodistribution and Imaging**

[0242] **Cell Culture and Animal Models.** Both PSMA-expressing (PSMA+ PC3-PIP) and non-

expressing (PSMA- PC3-flu) prostate cancer cell lines (Chang et al, Cancer Res., vol. 59, pp. 3192-3198, 1999) were grown in RPMI 1640 medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS) (Invitrogen) and 1% Pen-Strep (Biofluids, Camarillo, CA). All cell cultures were maintained in 5% carbon dioxide (CO<sub>2</sub>), at 37.0°C in a humidified incubator. Animal studies were undertaken in compliance with the regulations of the Johns Hopkins Animal Care and Use Committee. Six- to eight-week-old male, non-obese diabetic (NOD)/severe-combined immunodeficient (SCID) mice (Charles River Laboratories, Wilmington, MA) were implanted subcutaneously (s.c.) with PC3-PIP and PC3-flu cells ( $2 \times 10^6$  in 100  $\mu$ L of Matrigel) at the forward left and right flanks, respectively. Mice were imaged or used in *ex vivo* biodistribution assays when the xenografts reached 5 to 7 mm in diameter.

**[0243] *In vivo* Imaging and *Ex vivo* Biodistribution.** Mouse #1 was injected with 10 nmol and mouse #2 with 1 nmol of YC-27 in 200  $\mu$ L of PBS intravenously (i.v.) *via* the lateral tail vein. Mouse #3 was injected with 1 nmol of YC-27 and also co-injected with 1  $\mu$ mol of the known PSMA inhibitor 2-{3-[1-carboxy-5-(4-iodo-benzoylamino)-pentyl]-ureido}-pentanedioic acid (DCIBzL) (Chen et al., J. Med. Chem., vol. 51, pp. 7933-7943, 2008; Barinka et al., J. Med. Chem. vol. 51, pp. 7737-7743, 2008) in 200 $\mu$ L of PBS i.v. to assess for PSMA binding specificity. Images were acquired at an array of post-injection (p.i.) time points starting at 10 min p.i. using a dedicated small animal optical imaging instrument, the Pearl Imager (LI-COR Biosciences). The Pearl Imager uses diffusive lasers optimized for IRDye 800CW. The instrument employs a CCD camera with a field-of-view of 11.2 cm  $\times$  8.4 cm at the surface of the imaging bed. The scan time was less than 30 sec to complete white light, 700 nm channel and 800 nm channel image acquisition. Images are displayed using a pseudocolor output with corresponding scale. All images were acquired at the same parameter settings and are scaled to the same maximum values. Imaging bed temperature was adjusted to 37°C. Animals received inhalational anesthesia (isoflurane) through a nose cone attached to the imaging bed. Animals were sacrificed by cervical dislocation for *ex vivo* imaging studies at the end of acquisition of the *in vivo* images. *Ex vivo* images were acquired first by midline surgical laparotomy and then again by harvesting liver, spleen, stomach, small intestine, kidneys, urinary bladder, PC3-PIP and PC3-flu tumors and displaying them individually on plastic Petri dishes. Estimates of signal output were provided by drawing three circular regions of interest within each tumor and determining the average signal (arbitrary units)/area using the manufacturer's software.

**[0244] Figure 11** (mouse #1) depicts the pharmacokinetic behavior of YC-27 *in vivo*. In this experiment 10 nmol of YC-27 was administered intravenously and the animal was imaged repeatedly over a three day period. Although difficult to quantify as these are planar images, one can see clearly increased uptake in the PSMA+ PC3-PIP tumor relative to the control (PSMA-negative) PC3-flu tumor at 18.5 h p.i. through 70.5 h p.i. (**Figure 11C through 11M**). Using quantitative real time polymerase chain reaction (qRT-PCR) we measured the relative amounts of PSMA mRNA expression in extracts of the tumors in mice #1-3, and confirmed that PC3-PIP tumors (left flank) expressed PSMA mRNA at levels several million times higher than PC3-flu tumors (right flank) (data not shown). Panels **11L** and **11M** show emission from the intact, living, unshaven animal, while panels **11N** and **11O** are postmortem studies with organs

exposed. Note that in **11L** one can barely discern the kidneys, a known target site for PSMA (Tasch et al., Crit. Rev. Immunol., vol. 21, pp. 249-261, 2001; Pomper et al., Mol. Imaging, vol. 1, pp. 96-101, 2002; Kinoshita et al., World J. Surg., vol. 30, pp. 628-636, 2006), while the kidneys are clearly visible in **11O** when exposed. A portion of that renal light emission may be due to clearance of this relatively hydrophilic compound. The estimated target-to-nontarget ratio (PC-3 PIP vs. PC-3 flu light output) was 10 when comparing the tumors from panel M (70.5 h p.i.).

**[0245]** The experiment in **Figure 12** was performed with 10-fold less **YC-27** administered than in the previous experiment. Despite reducing the concentration of **YC-27**, PSMA+ PC3-PIP tumor could be seen clearly at one day p.i. (**Figure 12**, mouse #2, *Left Panels*). DCIBzL, a known, high-affinity PSMA inhibitor, was co-administered with **YC-27** as a test of binding specificity (**Figure 12**, mouse #3, *Right Panels*). Nearly all of the light emission from target tumor, as well as kidneys, was blocked, demonstrating the specificity of this compound for PSMA *in vivo*. The estimated target-to-nontarget ratio (PC-3 PIP vs. PC-3 flu light output) was 26 when comparing the tumors from panel F (20.5 h p.i.). By administering 1 nmol to this ~ 25 g mouse, we have realized the high sensitivity of *in vivo* optical imaging, rivaling that of the radiopharmaceutical-based techniques. For example, 1 nmol converts to 1.6  $\mu\text{g}$  injected. If we synthesized a similar compound labeled with  $^{18}\text{F}$  or other radionuclide at 1,000 mCi/ $\mu\text{mol}$  (37 GBq/ $\mu\text{mol}$ ), and administered a standard dose of 200  $\mu\text{Ci}$  (7.4 MBq) to a mouse, we would be injecting 0.3  $\mu\text{g}$ .

**[0246]** Interestingly, in mouse #1, which received 10 nmol of **YC-27**, we observed a small degree of non-specific uptake at the 23 h time point, manifested as uptake within PSMA-negative PC3-flu tumors. That finding could be due to enhanced permeability and retention of **YC-27**. No non-specific uptake/retention was observed at a similar, 20.5 h, time point in mouse #2, which received a 10-fold lower dose. That finding suggests the need for further optimization of dose and timing for *in vivo* applications.

## **Discussion**


**[0247]** A wide variety of low molecular weight PSMA-based imaging agents have been synthesized, including those using the urea scaffold (Banerjee et al., J. Med. Chem., vol. 51, pp. 4504-4517, 2008; Chen et al., J. Med. Chem., vol. 51, pp. 7933-7943, 2008; Zhou et al., Nat. Rev. Drug Discov., vol. 4, pp. 1015-1026, 2005; Pomper et al., Mol. Imaging, vol. 1, pp. 96-101, 2002; Foss et al., Clin. Cancer Res., vol. 11, pp. 4022-4028, 2005; Humblet et al., Mol. Imaging, vol. 4, 448-462, 2005; Misra et al., J. Nucl. Med., vol. 48, pp. 1379-1389, 2007; Mease et al., Clin. Cancer Res., vol. 14, pp. 3036-3043, 2008; Liu et al., Prostate, vol. 68, pp. 955-964, 2008; Humblet et al., J. Med. Chem., vol. 52, pp. 544-550, 2009; Kularatne et al., Mol. Pharm., vol. 6, pp. 790-800, 2009; Hillier et al., Cancer Res., vol. 69, pp. 6932-6940, 2009). Those compounds have primarily been radiopharmaceuticals, but optical agents exist. In two separate studies Humblet et al. reported the synthesis of mono- and polyvalent NIR

fluorescent phosphonate derivatives for imaging PSMA, but little accumulation in PSMA-expressing tumors was evident in the former study (Humblet et al., Mol. Imaging, vol. 4, pp. 448-462, 2005) while no *in vivo* results were reported in the latter (Humblet et al., J. Med. Chem., vol. 52, pp. 544-550, 2009). Liu et al have also synthesized fluorescent phosphonate derivatives and have demonstrated their PSMA-binding specificity and intracellular localization *in vitro* (Liu et al., Prostate, vol. 68, pp. 955-964, 2008). Recently Kularatne et al. have synthesized fluorescent (fluorescein and rhodamine) urea derivatives that demonstrate PSMA migration to endosomes (Kularatne et al., Mol. Pharm., vol. 6, pp. 790-800, 2009). We arrived at **YC-27** based on structure-activity relationships developed for PSMA-binding ureas, which were focused on improving pharmacokinetics for use *in vivo* by optimization of the linker-chelate complex (Banerjee et al., J. Med. Chem., vol. 51, pp. 4504-4517, 2008). Calculated hydrophobicity values (Ghose et al., J. Phys. Chem. A, vol. 102, pp. 3762-3772, 1998) suggest that **YC-27** should be considerably more hydrophobic (ALogD = 5.96) than radiopharmaceuticals such as [<sup>125</sup>I]DCIBzL (ALogD = 1.19), perhaps accounting for its long tumor retention, which is desirable for an optical imaging agent intended for intraoperative use. We confirmed greater hydrophobicity of **YC-27** relative to DCIBzL through reverse-phase HPLC (data not shown)

#### EXAMPLE 6 (not according to the invention)

#### Synthesis of YC-VIII-36

[0248]



[0249] To a solution of **YC-VIII-24** (prepared as described in Example 5) (1.5 mg, 0.21  $\mu\text{mol}$ ) in DMF (1 mL) was added triethylamine (0.005 mL, 35.9  $\mu\text{mol}$ ), followed by fluorescein isothiocyanate isomer 1 (1 mg, 2.57  $\mu\text{mol}$ ). After 2 hours at room temperature, the reaction mixture was purified by HPLC (column, Econosphere C18 5 $\mu$ , 150  $\times$  4.6 mm; retention time, 15 min; mobile phase, H<sub>2</sub>O/CH<sub>3</sub>CN/TFA = 75/25/0.1; flow rate, 1 mL/min) to afford 1.5 mg (72%) of compound **YC-VIII-36**. ESI-Mass calcd for C<sub>47</sub>H<sub>57</sub>N<sub>6</sub>O<sub>16</sub>S [M+H]<sup>+</sup> 993.4, found 992.8.

#### Cell Labeling

[0250] PSMA positive PIP cells, and PSMA negative FLU cells were treated with compound YC-VIII-36 (40nM) and 4',6-diamidino-2-phenylindole (DAPI, blue). **Figure 17** shows fluorescence of cells expressing PSMA (green fluorescence, top left). PIP and FLU cells were treated with both YC-VIII-36 and PSMA inhibitor PMPA (5  $\mu$ M), showing inhibition of cellular fluorescence by PMPA (**Figure 17**, bottom).

[0251] **Figure 18** shows PC3-PIP cells treated with DAPI (blue) and varying concentrations of YC-VIII-36 (green).

[0252] **Figure 19** shows time dependent internalization of YC-VIII-36 into PC3-PIP cells treated with YC-VIII-36 (green) and DAPI (blue). The time dependent internalization study was done as described (Liu et al., Prostate vol. 68, pp. 955-964, 2008) with appropriate modifications. Briefly, PC3-PIP cells were seeded as above. The cells were first pre-chilled by incubating with ice cold complete growth media and then incubated with ice cold complete growth media containing 500 nM of compound YC-VIII-36 at 40 C for 1 hr. After 1hr of incubation the excess compound was removed by washing the wells twice with ice-cold complete growth media and then the wells were replenished with pre-warmed complete growth media. The chamber slides containing cells were incubated for 10 min, 30 min, 60 min and 180 min at 37°C in a humidified incubator.

### In vivo Imaging

[0253] **Figure 20** shows titration and detection of varying amounts of YC-VIII-36 injected subcutaneously into a nude mouse. (IVIS spectrum with 10 second exposure followed by spectral unmixing)

[0254] **Figure 21 and 22** (top) shows fluorescence images of a PSMA+ PC3-PIP and PSMA- PC3-flu tumor-bearing mouse injected intravenously with exemplary compound YC-VIII-36. Compound YC-VIII-36 (150  $\mu$ g) was injected into the tail vein of a nude mouse. The excitation frequency was 465 nm with a 5 s exposure. Fluorescence emission was measured at 500, 520, 540, and 580 nm, followed by spectral unmixing.

[0255] **Figure 22** (bottom) shows the biodistribution of compound YC-VII-36 (150  $\mu$ g) 180 minutes after injection.

### FACS and Cell Sorting

[0256] *Flow cytometric analysis (FCA)*: Confluent flasks of PC3-PIP, PC3-flu and LNCap cells were trypsinized, washed with complete growth media (to neutralize trypsin) and counted. Approximately 5 million of each cell type in suspension was incubated with 1mM of compound YC-VIII-36 for 30 min with occasional shaking at 37°C in the humidified incubator with 5% CO<sub>2</sub>.

After incubation, the cells were washed twice with ice cold KRB buffer and fixed with 2% paraformaldehyde (ice cold). The samples were stored on ice and protected from light until the FCA was done. FCA was performed using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA). For data acquisition, singlets were gated as the prominent cluster of cells identified from a plot of side scatter (SSC) width versus forward scatter (FSC) width to ensure that cell aggregates were excluded from analysis. 50,000 total events were counted to estimate the positively stained cells from a plot of FI-1 (X-axis) versus FI-2 (Y-axis). All data were analyzed using CellQuest version 3.3 software.

**[0257]** Flow sorting: PC3-PIP cells were labeled with 1mM of compound **YC-VIII-36** for 30 min at 37°C in the humidified incubator with 5% CO<sub>2</sub>. Cells were washed twice with ice cold KRB buffer and stored on ice. Flow sorting was performed using FACS Aria system (Becton Dickinson, San Jose, CA) within 10-15 minutes after completion of last wash. Both the stained (positive) and also the unstained (negative) subpopulations were collected in sterile tubes containing 3 ml of complete growth media. Following sorting, cells were centrifuged, resuspended in warm complete growth media, transferred to tissue culture flasks and incubated at 37°C in the humidified incubator with 5% CO<sub>2</sub> for culture. The sorted subpopulations, "PIP-positive (PIP-pos)" and "PIP-negative (PIP-neg)" cells, were re-analyzed by FCA (as above) at passage 3 for further confirmation of their heterogeneity.

**[0258]** *Determination of saturation dose in flow cytometry:* Approximately 5 million cells each of PIP-pos (sorted) and PC3-flu were labeled as above with varying doses of compound #. The cells were washed twice with ice cold KRB buffer and fixed with 2% paraformaldehyde (ice cold). The samples were stored on ice and protected from light till the FCA was done. Singlets were gated as above in a plot of SSC vs. FSC to exclude the aggregates. Standard gating was used on X-axis (FI-1) for analysis of stained cells in all the doses.

**[0259]** PC3-flu, PC3-PIP, and LNCaP cells were treated with compound YC-VIII-36, and analyzed using fluorescence activated cell sorting (FACS) to determine the percentage of cells expressing PSMA on the cell surface. **Figure 23** shows FACS analysis showing the percent subpopulation of PSMA positive cells in PC3-flu, PC3-PIP, and LNCaP cells. As expected PC3-flu (PSMA-) cells (left) show a very small percentage, while PC3-PIP (PSMA+, center) and LNCaP (PSMA+ right) show greater percentages.

**[0260]** PC3-PIP (PSMA+) cells were sorted using FACS following treatment with compound YC-VIII-36. **Figure 24** shows cell sorting of PC3-PIP cells, including initial percentage (top center), and after 3 passages of sorting (bottom). Region R2 indicates positive PSMA surface expression, as indicated by binding compound YC-VIII-36. The results show an increase in the percentage of PSMA expressing cells following three rounds of cell sorting.

**[0261]** *Determination of detection limit (Figure 25):* PIP-pos cells were mixed with 10 million of PC3-flu cells in triplicates in different ratios- 1 in 10<sup>6</sup>, 10<sup>5</sup>, 10<sup>4</sup>, 10<sup>3</sup> and 10<sup>2</sup> respectively. All the tubes containing cell suspensions in complete growth media including controls [10 million PC3-

flu cells with 0% PIP-pos cells and 10 million PIP-pos cells (100%)] were incubated with 100 nM of compound # **YC-VIII-36** at 37°C in the humidified incubator with 5% CO<sub>2</sub> as above, with occasional stirring. The cells were washed, fixed with 2% paraformaldehyde as above and analyzed with LSRII (Becton Dickinson, San Jose, CA) for the determination of detection limit. Singlets were gated as above in a plot of SSC vs. FSC to exclude the aggregates. 1 million total events were counted to estimate the positively stained cells from plot of FI-1 (X-axis) versus FI-2 (Y-axis). Two gates, P2 at higher intensity (103 and above) and P3 at lower intensity (102-103) on X-axis (FI-1) was applied for analysis of positive cells as described in figure 4. All the data were analyzed using DIVA 6.1.3 software.

## REFERENCES CITED IN THE DESCRIPTION

### Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Patent documents cited in the description


- [US61161484 \[0001\]](#)
- [US61161485B \[0001\]](#)
- [US61248067B \[0001\]](#)
- [US61248934B \[0001\]](#)
- [WO2009026177A1 \[0008\]](#)
- [WO2009002529A2 \[0008\]](#)
- [WO2008109832A \[0092\]](#)

### Non-patent literature cited in the description

- Cancer Facts & Figures American Cancer Society 20090000 [0003]
- **CHANG et al.** Cancer Res., 1999, vol. 59, 3192-3198 [0004] [0242]
- **CHANG et al.** Clin. Cancer Res., 1999, vol. 5, 2674-2681 [0004]

- **GONG et al.** Cancer Metastasis Rev., 1999, vol. 18, 483-490 [0004]
- **CHANG et al.** Mol. Urol., 1999, vol. 3, 313-320 [0004]
- **BACCALA et al.** Urology, 2007, vol. 70, 385-390 [0004] [0004]
- **CHANG et al.** Urology, 2001, vol. 57, 801-805 [0004]
- **MILOWSKY et al.** J. Clin. Oncol., 2007, vol. 25, 540-547 [0004] [0004]
- **MURPHY et al.** Urology, 1998, vol. 51, 89-97 [0004]
- **GALSKY et al.** J Clin Oncol, 2008, vol. 26, 2147-2154 [0004]
- **LANGE, P. H.** Urology, 2001, vol. 57, 402-406 [0005]
- **HASEMAN et al.** Cancer Biother Radiopharm, 2000, vol. 15, 131-140 [0005]
- **ROSENTHAL et al.** Tech Urol, 2001, vol. 7, 27-37 [0005]
- **TODA** Keio J. Med., 2008, vol. 57, 155-161 [0007] [0007]
- **OKUDA et al.** Minim. Invasive Neurosurg., 2007, vol. 50, 382-384 [0007]
- **STUMMER et al.** Lancet Oncol., 2006, vol. 7, 392-401 [0007]
- **ARNDT-JOVIN et al.** IEEE Trans Nanobioscience, 2009, [0007]
- **GOTOH et al.** J. Surg. Oncol., 2009, [0007]
- **MATSUI et al.** Plast. Reconstr. Surg., 2009, vol. 123, 125e-127e [0007]
- **KAUSHAL et al.** J. Gastrointest. Surg., 2008, vol. 12, 1938-1950 [0007]
- **SHETH et al.** Gynecol. Oncol., 2009, vol. 112, 616-622 [0007]
- **REUBI et al.** J Nucl Med, 2008, vol. 49, 1735-1738 [0008]
- **SANCHEZ-CRESPO et al.** Eur J Nucl Med Mol Imaging, 2004, vol. 31, 44-51 [0008] [0008]
- **KHAN et al.** Eur J Surg Oncol, 2009, vol. 35, 561-567 [0008]
- ; **FANI et al.** Contrast Media Mol Imaging, 2008, vol. 3, 67-77 [0008]
- **CHANDRAN et al.** Characterization of a Targeted Nanoparticle Functionalized with a Urea-Based Inhibitor of Prostate Specific Membrane Antigen (PSMA) Cancer Biology & Therapy, 2008, vol. 7, 6974-982 [0008]
- **BANERJEE et al.** Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA) J. Med. Chem., 2008, vol. 51, 4504-4517 [0008]
- **CHEN et al.** Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer J. Med. Chem., 2008, vol. 51, 7933-7943 [0008]
- **MARESCA et al.** A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer J. Med. Chem., 2009, vol. 52, 347-357 [0008]
- **WUTZ et al.** Greene's Protective Groups in Organic Synthesis Wiley-Interscience 2007 0000533-643 [0042]
- Remington's Pharmaceutical Sciences Mack Publishing Company 1985 00001418- [0128]
- **BANERJEE et al.** J. Med. Chem., 2008, vol. 51, 4504-4517 [0130] [0212] [0247] [0247]
- Remington's Pharmaceutical Sciences Mack Publishing Company 1990 0000 [0155]
- **BANERJEE et al.** J Med Chem, 2008, vol. 51, 4504-4517 [0169] [0171] [0183] [0197] [0199]
- **ZHERNOSEKOV et al.** J Nucl Med, 2007, vol. 48, 1741-1748 [0179]
- **MEASE et al.** Clin Cancer Res, 2008, vol. 14, 3036-3043 [0180] [0199]

- HAMACHI et al. Chem. Eur. J., 1999, vol. 5, 1503-1511 [0183]
- KAISER et al. Anal Biochem, 1970, vol. 34, 595-598 [0185]
- ANTUNES et al. Bioconjug Chem, 2007, vol. 18, 84-92 [0187] [0188]
- KOZIKOWSKI et al. J Med Chem, 2004, vol. 47, 1729-1738 [0189]
- CHANG et al. Cancer Res, 1999, vol. 59, 3192-3198 [0191] [0209]
- SILVER et al. Clin Cancer Res, vol. 3, 81-85 197- [0192] [0194] [0198] [0203] [0204]
- SLUSHER et al. J Comp Neurol, 1992, vol. 315, 271-229 [0192] [0194] [0198] [0203] [0204]
- JACKSON et al. J Med Chem, 1996, vol. 39, 619-622 [0197]
- LAPI et al. J Nucl Med, 2009, vol. 50, 2042-2048 [0199]
- WANG et al. Nature Protocols, 2006, vol. 1, 1477-1480 [0207]
- BANERJEE et al. J. Med. Chem., 2008, vol. 51, 4507-4517 [0217]
- SEVICK-MURACA et al. Photochem. Photobiol., 1997, vol. 66, 55-64 [0238] [0239]
- K. GOTOHT. YAMADAO. ISHIKAWAH. TAKAHASHIH. EGUCHIM. YANOH. OHIGASHIY. TOMITAY. MIYAMOTOS. IMAOKAA novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation J. Surg. Oncol., 2009, [0239]
- CHEN et al. J. Med. Chem., 2008, vol. 51, 7933-7943 [0240] [0243] [0247]
- ZHOU et al. Nat. Rev. Drug Discov., 2005, vol. 4, 1015-1026 [0241] [0247]
- BARINKA et al. J. Med. Chem., 2008, vol. 51, 7737-7743 [0243]
- TASCH et al. Crit. Rev. Immunol., 2001, vol. 21, 249-261 [0244]
- POMPER et al. Mol. Imaging, 2002, vol. 1, 96-101 [0244] [0247]
- KINOSHITA et al. World J. Surg., 2006, vol. 30, 628-636 [0244]
- FOSS et al. Clin. Cancer Res., 2005, vol. 11, 4022-4028 [0247]
- HUMBLET et al. Mol. Imaging, 2005, vol. 4, 448-462 [0247] [0247]
- MISRA et al. J. Nucl. Med., 2007, vol. 48, 1379-1389 [0247]
- MEASE et al. Cancer Res., 2008, vol. 14, 3036-3043 [0247]
- LIU et al. Prostate, 2008, vol. 68, 955-964 [0247] [0247] [0252]
- HUMBLET et al. J. Med. Chem., 2009, vol. 52, 544-550 [0247] [0247]
- KULARATNE et al. Mol. Pharm., 2009, vol. 6, 790-800 [0247] [0247]
- HILLIER et al. Cancer Res., 2009, vol. 69, 6932-6940 [0247]
- GHOSE et al. J. Phys. Chem. A, 1998, vol. 102, 3762-3772 [0247]

**Patentkrav****1. Forbindelse med strukturen:**

5 hvor:

Z er tetrazol eller CO<sub>2</sub>Q;

hvert Q er uafhængigt valgt fra hydrogen eller en beskyttelsesgruppe;

a er 1, 2, 3 eller 4;

R er hvert uafhængigt H eller C<sub>1</sub>-C<sub>4</sub>-alkyl;

10

Ch er en metalchelaterende del, som eventuelt inkluderer et chelateret metal, hvor Ch yderligere inkluderer yderligere atomer eller linkere, som er nødvendige for at forbinde den metalchelaterende del til resten af forbindelsen;

W er -NRC(O)-, -NRC(O)NR-, NRC(S)NR-, -NRC(O)O-, -OC(O)NR-, -OC(O)-, -C(O)NR- eller -C(O)O-;

15

Y er -C(O)-, -NRC(O)-, -NRC(S)-, -OC(O);

V er -C(O)-, -NRC(O)-, -NRC(S)- eller -OC(O)-;

m er 1, 2, 3, 4, 5 eller 6;

n er 1, 2, 3, 4, 5 eller 6;

20

p er 2;

R<sup>1</sup> er C<sub>2</sub>-C<sub>12</sub>-aryl, som indeholder 1 til 3 separate eller fusionerede ringe og 0, 1, 2 eller 3 heteroatomer som ringelementer, hvor arylen kan være substitueret eller ikke-substitueret, og R<sup>1</sup> kan være det samme eller forskelligt;

25

R<sup>2</sup> og R<sup>3</sup> er uafhængigt H, CO<sub>2</sub>H eller CO<sub>2</sub>R<sup>4</sup>, hvor R<sup>4</sup> er en C<sub>1</sub>-C<sub>6</sub>-alkyl, hvor en af R<sup>2</sup> og R<sup>3</sup> er CO<sub>2</sub>H eller CO<sub>2</sub>R<sup>4</sup>, den anden er H.




valgt fra gruppen bestående af halogen, cyano, hydroxyl, nitro, azido, amino, alkanoyl, carboxamido, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, alkylthio, alkylsulfanyl, alkylsulfonyl, aminoalkyl, carbocyklisk aryl, arylalkyl, arylalkoxy og en mættet, umættet eller aromatisk heterocyklisk gruppe, kan være yderligere 5 substitueret.



**5.** Forbindelsen ifølge et hvilket som helst af kravene 1 til 4, hvor de yderligere atomer eller linkere, som er nødvendige for at forbinde den metalchelaterende del til resten af forbindelsen omfatter en alkyl, aryl, kombination af alkyl og aryl, eller 10 alkyl- og arylgrupper med heteroatomer.





**6.** Forbindelsen ifølge krav 5, hvor de yderligere atomer eller linkere, som er nødvendige for at forbinde den metalchelaterende del til resten af forbindelsen, omfatter en alkylgruppe, hvor alkylgruppen kan være substitueret eller ikke- 15 substitueret.

**7.** Forbindelsen ifølge et hvilket som helst af kravene 1 til 6, hvor Ch omfatter en struktur valgt fra gruppen bestående af:



20





8. Forbindelsen ifølge et hvilket som helst af kravene 1 til 7, hvor Ch omfatter
- 10 1,4,7,10-tetraazacyclododecan-1,4,7,10-tetraeddikesyre (DOTA).
9. Forbindelsen ifølge et hvilket som helst af kravene 1 til 8, hvor Ch omfatter et chelateret metal, og det chelaterede metal omfatter en radioaktiv isotop.
- 15 10. Forbindelsen ifølge krav 9, hvor den radioaktive isotop er Tc-99m, In-111, Ga-67, Ga-68, Y-86, Y-90, Lu-177, Re-186, Re-188, Cu-64, Cu-67, Co-55, Co-57,

Sc-47, Ac-225, Bi-213, Bi-212, Pb-212, Sm-153, Ho-166 eller Dy-166.

**11.** Forbindelsen ifølge krav 10, hvor den radioaktive isotop er Ga-68 eller Lu-177.

5

**12.** Forbindelsen ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i:

(a) en fremgangsmåde til billeddannelse af en eller flere celler, organer eller vævstyper ved at eksponere cellen for eller indgive en organisme en effektiv mængde af forbindelsen, hvor forbindelsen inkluderer en metalisotop, der er egnet til billeddannelse; eller

10

(b) en fremgangsmåde til behandling af en tumor omfattende indgivelse af forbindelsen, hvor forbindelsen inkluderer en terapeutisk effektiv radioisotop.

15 **13.** Kit omfattende en forbindelse ifølge et hvilket som helst af kravene 1-11.

# DRAWINGS

Drawing




FIG. 1




FIG. 2





FIG. 3



- (a) 20% PERIDINE IN DMF; Fmoc-Phe-OH, HBTU, HOBT, DIEA, DMF;  
 (b) 20% PERIDINE IN DMF; Fmoc-Phe-OH, HBTU, HOBT, DIEA, DMF;  
 20% PERIDINE in DMF  
 (c) DOTA-tris(tert-butylester)-CO<sub>2</sub>H, HBTU, HOBT, DIEA, DMF;  
 (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, t, OVERNIGHT;  
 (e) DSS-urea, TEA, DMF, rt, OVERNIGHT;  
 (f) <sup>111</sup>InCl<sub>3</sub>, 200 mM NaOAc, 60°C, 30 min

FIG. 4




FIG. 5




FIG. 6





FIG. 7



QUANTUM YIELD OF YC-27.3 IN WATER = 0.053  
REF Q.Y. (ICG IN WATER) = 0.016

OD<sub>ICG</sub> = 0.035 ( $\lambda$  = 775 nm) Em SPECTRA AREA = 6276

OD<sub>YC27</sub> = 0.05 ( $\lambda$  = 775 nm) Em SPECTRA AREA = 29509

FOR QUANTUM YIELD MEASUREMENTS, 775 nm EXCITATION WAVELENGTH USED,  
INTEGRATED AREA FROM EMISSION SPECTRA IN THE REGION 780-900 nm USED

FIG. 8




FIG. 9




FIG. 10






FIG. 11N




FIG. 11O




FIG. 12A FIG. 12B




FIG. 12A FIG. 12B




FIG. 12C FIG. 12D




FIG. 12C FIG. 12D




FIG. 12E FIG. 12F




FIG. 12E FIG. 12F




FIG. 12G FIG. 12H




FIG. 12G FIG. 12H




FIG. 12I FIG. 12J





FIG. 12I FIG. 12J






8 hr




3 hr




30 MIN

FIG. 13



1.25 h




3 h


FIG. 14



5h



3h



30 MIN


FIG. 15



5 h



3 h



30 MIN

FIG. 16




FIG. 17




FIG. 18








FIG. 19

GFP-QD-SET (TOGETHER)



QD-SET (EX-500, EM-540)



GFP-SET (EX-465, EM-520)





FIG. 20




FIG. 21






FIG. 22




FILE: LN CAP.006  
 ACQUISITION DATE: 23-JUL-09  
 GATE: G1  
 GATED EVENTS: 11179

QUAD	EVENTS	% GATED
UL	0	0.00
UR	137	1.23
LL	1290	11.54
LR	9752	87.23



FILE: PIP.004  
 ACQUISITION DATE: 23-JUL-09  
 GATE: G1  
 GATED EVENTS: 10528

QUAD	EVENTS	% GATED
UL	2	0.02
UR	8	0.08
LL	8636	82.03
LR	1862	17.88



FILE: FLU.002  
 ACQUISITION DATE: 23-JUL-09  
 GATE: G1  
 GATED EVENTS: 10805

QUAD	EVENTS	% GATED
UL	9	0.08
UR	5	0.05
LL	10718	99.19
LR	73	0.68

FIG. 23










FIG. 24



TO  
FIG. 25B

FIG. 25A



FROM  
FIG. 25A

TO  
FIG. 25C




FIG. 25B

FROM  
FIG. 25B




FIG. 25C